On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize meningiomas as the most prevalent primary intracranial tumor, representing nearly 40% of all CNS neoplasms. They arise from the arachnoid cap cells and are most frequently diagnosed in the sixth and seventh decades of life, with a median age of 66 years.
- •Identify the strong female predominance, with women affected at roughly twice the rate of men. This disparity is largely attributed to the expression of estrogen and progesterone receptors within the tumor cells, and risk is further modified by exogenous hormone use, such as high-dose progestins or hormone replacement therapy.
- •Screen for the most significant environmental risk factor: prior exposure to ionizing radiation. Radiation-induced meningiomas (RIMs) often appear 20–30 years after cranial irradiation for childhood malignancies or tinea capitis and are characterized by more aggressive biological behavior, multifocality, and higher histological grades.
- •Differentiate between the two primary molecular pathways: NF2-mutated and NF2-wildtype. Approximately 50-60% of sporadic cases involve inactivation of the NF2 gene on chromosome 22q, leading to the loss of the tumor suppressor Merlin, while non-NF2 variants often harbor mutations in TRAF7, AKT1, KLF4, or SMO.
- •Assess for genetic predisposition syndromes in patients presenting with multiple meningiomas or at a young age. is the most common, but other rare syndromes include BAP1 tumor predisposition syndrome (linked to aggressive rhabdoid variants) and Rubinstein-Taybi syndrome.
Evaluation
- •Suspect meningioma in patients presenting with new-onset focal seizures, progressive headaches, or location-specific neurological deficits. Seizures occur in approximately 30% of symptomatic patients and are often associated with peritumoral brain edema (PTBE).
- •Perform a detailed cranial nerve survey based on tumor location. For olfactory groove lesions, test for anosmia; for spheno-orbital tumors, evaluate for proptosis and visual field defects; and for cerebellopontine angle lesions, assess for hearing loss or facial nerve weakness.
- •Order a high-resolution MRI with and without gadolinium as the primary diagnostic modality. Look for a well-circumscribed, dural-based mass that is isointense on T1 and T2 sequences and demonstrates robust, homogeneous enhancement with a characteristic "dural tail sign."
- •Utilize Fluid-Attenuated Inversion Recovery (FLAIR) sequences to quantify peritumoral brain edema. Significant edema often correlates with higher tumor grade, brain invasion, or specific molecular markers like FOXC1 expression.
- •Obtain a non-contrast CT scan to evaluate for bone involvement. Meningiomas frequently cause reactive hyperostosis (thickening of the adjacent bone) or may contain internal calcifications (psammoma bodies) in 20-25% of cases.
- •Consider in complex cases or for recurrence monitoring. Because meningiomas nearly universally overexpress somatostatin receptor 2 (SSTR2), this modality is highly sensitive for delineating tumor margins in the skull base or distinguishing tumor from post-radiation changes.
- •Apply the 2021 WHO Classification criteria to determine tumor grade. Grade 1 is benign (<4 mitoses/10 HPF); Grade 2 is atypical (4-19 mitoses, brain invasion, or specific histology like clear cell/chordoid); and Grade 3 is anaplastic (≥20 mitoses or frank malignancy).
- •Identify high-risk molecular markers that override histological appearance. The presence of TERT promoter mutations or CDKN2A/B homozygous deletions automatically classifies a tumor as WHO Grade 3, regardless of the mitotic count.
- •Use immunohistochemistry (IHC) surrogates for molecular testing when NGS is unavailable. Loss of MTAP expression is a reliable surrogate for CDKN2A deletion, and loss of Merlin expression suggests NF2 alteration.
- •Evaluate the Ki-67 (MIB-1) proliferation index to estimate recurrence risk. While thresholds vary, a Ki-67 index >5-10% is generally associated with more aggressive growth and a higher likelihood of progression after resection.
- •Rule out mimics of dural-based lesions, such as (SFT), which is distinguished by STAT6 nuclear expression, or primary dural lymphoma, which typically shows restricted diffusion on MRI.
- •Assess for venous sinus involvement in parasagittal tumors. Use MR venography (MRV) to determine if the superior sagittal sinus is patent, partially compressed, or completely occluded, as this significantly impacts surgical planning and risk.
Management
- •Adopt a "wait-and-scan" strategy for asymptomatic, incidental WHO Grade 1 meningiomas. Perform a baseline follow-up MRI at 6 months, then annually if stable; for elderly patients with small lesions, observation is often the definitive management.
- •Pursue maximal safe surgical resection as the primary treatment for symptomatic or growing tumors. The goal is a Simpson Grade I resection (complete removal of tumor, dural attachment, and involved bone) to minimize the risk of recurrence.
- •Administer perioperative corticosteroids, such as Dexamethasone 4-10 mg every 6 hours, to manage symptomatic peritumoral edema, tapering as soon as clinically feasible postoperatively.
- •Initiate anti-seizure medications (ASMs) in patients who have experienced a preoperative seizure. Routine prophylactic ASMs in seizure-naive patients are generally not recommended beyond the immediate postoperative week.
- •Utilize stereotactic radiosurgery (SRS) as primary treatment for small-to-medium (<3 cm or <8 cc) tumors in surgically high-risk areas like the cavernous sinus. A typical margin dose is 14-16 Gy for Grade 1 lesions.
- •Recommend fractionated radiotherapy (FSRT) for large tumors or those in close proximity to the optic apparatus. Standard dosing is 50.4-54 Gy delivered in 1.8 Gy fractions to minimize the risk of radiation-induced optic neuropathy.
- •Mandate adjuvant radiotherapy for all WHO Grade 3 (anaplastic) meningiomas and for WHO Grade 2 (atypical) tumors following subtotal resection (STR). Doses for high-grade disease are typically escalated to 60 Gy.
- •Consider hypofractionated stereotactic radiosurgery (HSRS), such as 25 Gy in 5 fractions, for medium-sized tumors to provide a high biological dose while sparing adjacent healthy tissue and reducing the risk of radiation-induced edema.
- •Refer patients with treatment-refractory, high-grade meningiomas for systemic therapy. Bevacizumab 10 mg/kg IV every 2 weeks is the most common first-line systemic agent for managing progressive disease and associated edema.
- •Evaluate candidates for Peptide Receptor Radionuclide Therapy (PRRT) using (Lutathera) 7.4 GBq every 8 weeks for 4 doses if SSTR2 expression is confirmed on PET imaging and standard options are exhausted.
- •Explore targeted inhibitors for specific mutations: Vismodegib 150 mg daily for SMO mutations, or Capivasertib 400 mg twice daily for AKT1 mutations, ideally within the context of a clinical trial.
- •Monitor for long-term complications of radiation, including SMART syndrome (stroke-like migraine attacks after radiation therapy) and radiation-induced cognitive decline, which may manifest years after treatment.
- •Schedule long-term surveillance imaging. For Grade 1 tumors, annual scans for 5 years then biennial; for Grade 2/3, scans every 3-6 months for the first 2-3 years, as recurrences can occur even a decade after initial treatment.
- •Refer to neuro-ophthalmology for patients with optic nerve sheath meningiomas or tumors involving the orbit to ensure formal visual field and acuity monitoring.
- •Discharge patients once they are neurologically stable and have adequate seizure control. Ensure they are aware that any new focal deficit or worsening headache requires immediate re-evaluation.
Board Review — High Yield
- •Dural Tail Sign — Thickening of the adjacent dura mater on MRI, highly characteristic of meningioma.
- •Psammoma Bodies — Laminated, whorled calcifications seen histologically in transitional and psammomatous subtypes.
- •NF2 (Merlin) — The most common genetic driver; loss of chromosome 22q is found in ~60% of cases.
- •SSTR2 — Somatostatin receptor 2, the biological target for 68Ga-DOTATATE PET imaging and PRRT.
- •Simpson Grade I — Complete resection of tumor, dura, and bone; associated with the lowest recurrence rate.
- •TERT Promoter Mutation — A molecular marker that defines WHO Grade 3 (malignant) regardless of histology.
- •Hyperostosis — Reactive bone thickening adjacent to the tumor, often requiring surgical drilling/resection.
- •Ionizing Radiation — The only well-established environmental risk factor for meningioma development.
Deep Dive — Evidence Details
Epidemiology and Risk Factors
- ▸Meningioma is the most common primary CNS tumor with a significant female predominance (AAIR **13.66** vs **6.75 per 100,000**).
- ▸Ionizing radiation is the most potent environmental risk factor, leading to radiation-induced meningiomas with long latencies and aggressive behavior.
- ▸Hormonal influences, including progestin-containing contraceptives and surgical menopause, significantly modulate individual risk.
Meningiomas are the most common primary central nervous system (CNS) tumors, originating from the arachnoid cap cells of the leptomeninges [29]D[30]D. While the majority follow a benign clinical course, their high prevalence and potential for morbidity make them a significant public health concern. In the United States, the average annual age-adjusted incidence rate (AAIR) is 10.33 per 100,000 population [30]D. Global reporting varies; for instance, pooled analysis from Nigeria indicates an extrapolated prevalence of 3.22 per 100,000 [7]. Although typically intracranial, metastatic dissemination beyond the cranial and spinal compartments occurs in 0.1% to 0.76% of cases, primarily involving the lungs, bone, and liver [29]D.
Demographic Distribution
Age and Sex: Meningioma incidence is strongly associated with advancing age, with the median age at diagnosis being 66 years [30]D. The AAIR peaks in the 85+ age group at 47.01 per 100,000 [30]D. There is a pronounced female predominance, with women exhibiting an AAIR of 13.66 per 100,000 compared to 6.75 per 100,000 in men [30]D. This disparity is attributed to the expression of estrogen and progesterone receptors within the tumor cells [17]D[29]D. In contrast, pediatric meningiomas are exceptionally rare, often presenting with seizures and requiring distinct strategies compared to adult cohorts [11].
Race and Ethnicity: In the United States, racial disparities are evident. Black individuals have a higher incidence rate (11.41 per 100,000) compared to White individuals (10.28 per 100,000) [30]D. These differences may reflect a combination of genetic predispositions and environmental exposures.
Established Risk Factors
Ionizing Radiation: Exposure to ionizing radiation is the most significant environmental risk factor for meningioma development [14]. Radiation-induced meningiomas (RIMs) are a recognized late complication of cranial irradiation for primary malignancies or [5][14]. RIMs are characterized by a long latency period (median 22–36 years) and often exhibit more aggressive biological behavior, including higher histological grades and multifocality, compared to spontaneous variants [5][14]. Survivors of childhood cancers are at particularly high risk, with risk levels correlating to the radiation dose received [21]D.
Hormonal Factors: The role of exogenous and endogenous hormones is a subject of intensive study. Surgical via bilateral salpingo-oophorectomy (BSO) has been associated with an increased risk of meningioma development [16]D. Furthermore, the use of hormone replacement therapy (HRT) and certain hormonal contraceptives, particularly those containing progestins, has been linked to increased risk in several large-scale registry studies [6][10]. Polycystic ovary syndrome (PCOS) and obesity, which alter the systemic hormonal environment, may further modify these risks [17]D.
Genetic Predisposition: While most meningiomas are sporadic, genetic factors play a crucial role in syndromic cases. Neurofibromatosis type 2 (NF2)-related schwannomatosis is the most well-characterized genetic driver, often leading to multiple meningiomas at an earlier age [24]D.
Emerging and Environmental Factors
Recent epidemiological research has explored environmental and metabolic associations. Ambient air pollution has been investigated as a potential carcinogen for CNS tumors, though a definitive link to meningioma remains poorly established [12]. Similarly, while obesity is a known risk factor for various malignancies, the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and meningioma risk remains uncertain and requires further longitudinal data [1]. Traumatic brain injury (TBI) has also been scrutinized; however, meta-analyses suggest that the association, if any, is weak (OR 1.0–1.2) and often confounded by detection bias [9].
Epidemiological Risk Assessment Protocol
For patients with incidental findings or high-risk histories, clinicians should follow a structured risk stratification protocol to determine the necessity of serial monitoring or intervention [24]D.
- Step 1: Initial Identification. Detect dural-based mass on imaging. Note that incidentalomas are found in approximately 4.5% of patients undergoing specialized imaging like 68Ga-DOTANOC PET/CT [20]D.
- Step 2: Risk Factor Review. Assess for history of cranial irradiation, NF2 status, and exogenous hormone use (e.g., high-dose progestins) [10][14].
- Step 3: Clinical Stratification. Utilize validated tools such as the IMPACT tool to integrate patient comorbidities and MRI characteristics (size, location) to decide between serial monitoring, surgical referral, or discharge [24]D.
| Risk Factor | Association / Magnitude | Evidence Level |
|---|---|---|
| Ionizing Radiation | High (Dose-dependent; long latency) | 2a [14] |
| Female Sex | AAIR 13.66 (vs 6.75 in males) | 5 [30]D |
| Black Race | AAIR 11.41 (vs 10.28 in Whites) | 5 [30]D |
| Progestin Use | Increased Risk (Registry-based) | 3b [10] |
| BSO | Increased Risk | 5 [16]D |
| Traumatic Brain Injury | OR 1.0–1.2 (Inconclusive) | 2a [9] |
| NF2 Mutation | High (Syndromic/Multiple tumors) | 5 [24]D |
Etiology and Molecular Pathogenesis
- ▸NF2 inactivation on chromosome 22q is the primary driver in ~60% of cases, leading to Hippo pathway dysfunction.
- ▸Non-NF2 meningiomas are driven by mutually exclusive mutations in TRAF7, AKT1, KLF4, or SMO, often correlating with specific anatomical locations like the olfactory groove.
- ▸BAP1-deficient meningiomas represent a distinct, aggressive molecular class with a high risk of recurrence and potential germline predisposition.
Meningiomas arise from the arachnoid cap cells of the leptomeninges and represent the most common primary intracranial neoplasm in adults [31][34]D. The etiology is multifactorial, involving a complex interplay between acquired somatic mutations, germline genetic predispositions, and environmental influences [35]D[58]D. While the majority of meningiomas are benign (WHO Grade 1), a significant subset exhibits aggressive clinical behavior and malignant transformation (MT), driven by specific molecular signatures and chromosomal instability [34]D[47]D. Recent epidemiological modeling suggests that a four-hit mechanism—the accumulation of four rate-limiting genetic or epigenetic steps—is sufficient for the development of benign meningiomas [60]D.
Genetic Drivers and Molecular Subtypes
The molecular landscape of meningioma is broadly divided into NF2-mutated and NF2-wildtype pathways [31][46]D.
- NF2 Inactivation: Inactivation of the NF2 gene on chromosome 22q is the most frequent driver event, occurring in approximately 50-60% of sporadic cases [50]D[56]D. The NF2 gene encodes Merlin, a tumor suppressor protein that links the cytoskeleton to cell surface glycoproteins. Loss of Merlin leads to the inactivation of the , resulting in the nuclear translocation of YAP/TAZ and subsequent oncogenic transcription [46]D[58]D. Merlin immunohistochemistry serves as a reliable surrogate marker, with complete loss of expression identifying 90% of tumors with NF2 alterations [50]D.
- Non-NF2 Drivers: Approximately 40% of meningiomas lack NF2 mutations and instead harbor mutually exclusive mutations in genes such as TRAF7, AKT1, KLF4, SMO, and PIK3CA [31][51]D.
- TRAF7: Often co-occurs with KLF4 (highly characteristic of secretory meningiomas) or AKT1 (E17K mutation) [31][51]D.
- SMO and SUFU: Associated with the , these are frequently found in olfactory groove meningiomas [31][49]D.
- AKT1: Mutations in AKT1 are linked to a higher risk of preoperative seizures [55]D.
Syndromic and Hereditary Predispositions
Several hereditary syndromes significantly increase the risk of developing single or multiple meningiomas:
- Neurofibromatosis Type 2 (NF2): An autosomal-dominant disorder caused by germline NF2 mutations, characterized by bilateral vestibular schwannomas and multiple meningiomas [37]D[43]D.
- Rubinstein-Taybi Syndrome (RTS): Caused by mutations in the CREBBP gene. While rare, RTS is considered a tumor predisposition syndrome where patients (predominantly female) may develop meningiomas harboring oncogenic CREBBP mutations [32]C.
- BAP1 Tumor Predisposition Syndrome: Germline or somatic BAP1 inactivation defines a highly aggressive subset of meningiomas, often with rhabdoid or papillary features and a high risk of relapse [41]C[48]D[54]D.
- Meningioangiomatosis (MA): A rare condition that can be sporadic or associated with NF2, characterized by plaque-like leptomeningeal proliferation [43]D.
Epigenetic and Chromosomal Mechanisms
Beyond point mutations, large-scale genomic alterations and epigenetic shifts drive pathogenesis and progression:
- KMT2C Loss: Loss of the histone methyltransferase KMT2C promotes progression in NF2-wildtype tumors by epigenetically repressing NF2 transcription and inactivating Hippo signaling [46]D.
- Loss of Y Chromosome (LOY): Observed in 9.7% of male meningiomas, LOY is significantly associated with higher WHO grades and poorer clinical outcomes [45]D.
- DNA Methylation: Distinct methylation classes can identify aggressive subtypes, such as BAP1-deficient tumors, even when histology appears non-rhabdoid [48]D[54]D.
- Malignant Transformation: The transition from Grade 1 to higher grades involves increased Ki-67 indices and specific molecular signatures, including TERT promoter mutations and CDKN2A/B homozygous deletions [31][47]D.
Environmental and Rare Triggers
- Lead (Pb) Exposure: Long-term exposure to lead promotes the proliferation of NF2-wildtype meningioma cells by interfering with the Merlin-Hippo signaling axis [58]D.
- Ectopic and Mimicry Lesions: Primary meningiomas can rarely occur in extracranial sites, such as the lungs (Primary Pulmonary Meningioma) or as minute pulmonary meningothelial-like nodules (MPMNs) [39]C[53]D. Additionally, can mimic the radiological and clinical presentation of meningioma [38]C.
Protocol: Molecular Stratification for Etiological Diagnosis
Step 1 → Perform Merlin immunohistochemistry and FISH for 22q to identify NF2-driven pathogenesis [50]D[52]D. Step 2 → If NF2 is intact, conduct targeted Next-Generation Sequencing (NGS) for TRAF7, AKT1, KLF4, and SMO to categorize the non-NF2 subtype [31][51]D. Step 3 → Assess for aggressive markers (BAP1 loss, TERT promoter mutation, CDKN2A/B deletion) in cases showing atypical features or rapid recurrence [31][35]D[54]D. Step 4 → In male patients or those with unusual presentations, evaluate for Y chromosome loss or germline predispositions (e.g., CREBBP for RTS) [32]C[45]D.
| Driver Mutation | Category | Frequency | Associated Subtype/Location | Key Reference |
|---|---|---|---|---|
| NF2 (Merlin loss) | Genetic (Somatic/Germline) | 50-60% | Conventional, Atypical, NF2 Syndrome | [31][50]D[56]D |
| TRAF7 | Genetic (Somatic) | ~25% | Secretory (with KLF4), Meningothelial | [31][51]D |
| AKT1 (E17K) | Genetic (Somatic) | ~10% | Meningothelial, Skull base, Seizure risk | [31][55]D |
| SMO / SUFU | Genetic (Somatic) | ~3-5% | Olfactory groove, Hedgehog pathway | [31][49]D |
| BAP1 | Genetic / Syndromic | Rare | Rhabdoid, Papillary, High-grade | [41]C[48]D[54]D |
| CREBBP | Syndromic (RTS) | Very Rare | Rubinstein-Taybi Syndrome | [32]C |
| KMT2C Loss | Epigenetic | Unknown | NF2-wildtype progression | [46]D |
| LOY (Y Loss) | Chromosomal | 9.7% (Males) | Higher WHO Grade (2/3) | [45]D |
Classification and WHO Grading
- ▸WHO Grade 2 is defined by a mitotic count of 4-19 per 10 HPF, brain invasion, or specific minor criteria, while Grade 3 requires ≥20 mitoses or specific molecular markers.
- ▸The 2021 WHO classification integrates TERT promoter mutations and CDKN2A/B homozygous deletions as standalone criteria for Grade 3 (anaplastic) meningioma.
- ▸MTAP immunohistochemistry serves as a vital surrogate marker for CDKN2A loss, facilitating accurate grading in resource-limited settings.
The classification of meningiomas has evolved from a purely morphological assessment to an integrated approach that combines histopathological features with molecular markers. The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System emphasizes this integration to improve risk stratification and predict biological behavior [79]D[80]D. Meningiomas are categorized into three grades (1, 2, and 3) based on their proliferative activity, presence of brain invasion, and specific genetic alterations [8][62].
WHO Grade 1 (Benign)
WHO Grade 1 meningiomas are the most common, representing approximately 80-85% of all cases [49]D. These tumors are characterized by slow growth and a low risk of recurrence following gross total resection. Histologically, they exhibit low mitotic activity (<4 mitoses per 10 high-power fields) and lack features of malignancy [8][79]D.
Common subtypes include meningothelial, fibrous (fibroblastic), and transitional meningiomas. Fibroblastic variants are frequently observed in specific locations such as the optic nerve sheath [68]C. Molecularly, many Grade 1 tumors are driven by NF2 gene alterations (22q loss or mutation). Merlin immunohistochemistry (IHC) serves as a reliable surrogate marker for these alterations, with complete loss of Merlin expression seen in 90% of NF2-altered cases [50]D.
WHO Grade 2 (Atypical)
WHO Grade 2 (atypical) meningiomas comprise approximately 15-18% of cases and exhibit more aggressive biological behavior [66]D. The diagnosis of a Grade 2 tumor is established if any of the following criteria are met:
- Mitotic count: 4 to 19 mitoses per 10 high-power fields (HPF) [8].
- Brain invasion: Direct infiltration of the brain parenchyma by the tumor [79]D.
- Minor criteria: Presence of at least three out of five specific features: spontaneous necrosis, sheeting (loss of whorling/fascicular architecture), prominent nucleoli, high cellularity, and small cells with a high nuclear-to-cytoplasmic ratio [79]D.
Specific histological variants, such as chordoid and clear cell meningiomas, are automatically classified as Grade 2 regardless of mitotic count [67]C[72]C. Clear cell meningiomas are rare, accounting for <1% of all meningiomas [67]C. Proliferation markers like Ki-67 (MIB-1) are increasingly used to refine prognosis, as higher indices correlate with reduced progression-free survival (PFS) [8][79]D. In males, the loss of the Y chromosome (LOY) is significantly associated with a higher likelihood of Grade 2 status (55.6% in LOY vs. 14.3% in non-LOY) [45]D.
WHO Grade 3 (Anaplastic/Malignant)
WHO Grade 3 meningiomas are rare (1-3%) but highly aggressive, with high recurrence rates and poor overall survival [69]. These tumors are defined by:
- Mitotic count: ≥20 mitoses per 10 HPF [79]D.
- Frank malignancy: Cytology resembling high-grade sarcomas, carcinomas, or melanomas [70]C.
- Molecular markers: The 2021 criteria allow for a Grade 3 diagnosis based on specific genetic alterations, even if the histology appears lower-grade. These include TERT promoter mutations and CDKN2A/B homozygous deletions [62][72]C.
MTAP immunohistochemistry is a critical surrogate marker for CDKN2A loss; its absence strongly suggests homozygous deletion and a Grade 3 designation [62]. Histological subtypes automatically graded as 3 include papillary and rhabdoid meningiomas [79]D.
Integrated Molecular and Radiomic Classification
Beyond standard grading, novel molecular classifications based on oxidative stress-related genes and PD-L1 expression patterns are being explored to identify therapeutic vulnerabilities [65][80]D. Radiomics and deep learning models are also emerging as non-invasive tools to predict tumor grade preoperatively by analyzing shape-based features like sphericity and surface regularity on MRI [81]D[84]D.
| WHO Grade | Histological Criteria | Molecular/Other Criteria |
|---|---|---|
| Grade 1 | <4 mitoses/10 HPF; benign subtypes | No brain invasion |
| Grade 2 | 4–19 mitoses/10 HPF; chordoid or clear cell subtypes | Brain invasion; or ≥3 minor criteria |
| Grade 3 | ≥20 mitoses/10 HPF; papillary or rhabdoid subtypes | TERT promoter mutation; CDKN2A/B deletion |
| Grade 1 (Benign) | Grade 2 (Atypical) | Grade 3 (Anaplastic) |
|---|---|---|
| Meningothelial | Atypical | Anaplastic (Malignant) |
| Fibrous (Fibroblastic) | Chordoid | Papillary |
| Transitional | Clear cell | Rhabdoid |
| Psammomatous | ||
| Angiomatous | ||
| Microcystic | ||
| Secretory | ||
| Lymphoplasmacyte-rich | ||
| Metaplastic |
Gross and Microscopic Features
- ▸Meningiomas are characterized by SSTR2 positivity but lack neuroendocrine markers like chromogranin or synaptophysin.
- ▸MTAP immunohistochemistry is a critical surrogate for CDKN2A loss, identifying tumors at high risk for aggressive progression.
- ▸Digital quantification of Ki-67 hotspots is superior to average counts for predicting recurrence-free survival.
The pathological evaluation of requires a synthesis of gross morphological characteristics, classic architectural patterns, and an increasingly complex array of immunohistochemical (IHC) and molecular markers. While most meningiomas exhibit benign behavior, their morphological diversity and the emergence of specific molecular signatures are critical for predicting recurrence and biological aggressiveness [97]D[104]D.
Gross Pathological Characteristics
Meningiomas typically present as well-circumscribed, globular, or lobulated masses with a firm dural attachment [90]C. Their consistency varies from soft and syncytial to tough and fibrous, often depending on the degree of collagen deposition or calcification.
- Growth Patterns: Most tumors grow as an exophytic "globular" mass that compresses the underlying brain parenchyma without direct invasion [68]C. However, the en plaque variant is characterized by a carpet-like growth along the , frequently associated with significant hyperostosis of the adjacent bone, as seen in sphenoorbital meningiomas [96]C.
- Location-Specific Features: Spinal meningiomas are often found in the thoracic segment, typically presenting as intradural extramedullary lesions that may cause significant spinal cord compression [88]C[92]C. In the optic nerve sheath, they may present as posterior intraconal tumors with an exophytic configuration [68]C.
- Metastatic Presentation: Although rare (incidence <1%), meningiomas can present as solitary pulmonary metastases, even decades after the primary low-grade tumor was treated [89]C.
Microscopic Hallmarks and Architecture
The microscopic diagnosis of meningioma relies on identifying classic architectural features, though these can vary significantly across histological subtypes.
- Whorl Formation and Psammoma Bodies: The most characteristic feature is the arrangement of cells in concentric whorls. Over time, these whorls may undergo hyalinization and calcification, forming laminated psammoma bodies.
- Cellular Features: Cells typically possess indistinct cell borders (syncytial appearance), eosinophilic cytoplasm, and oval nuclei with delicate chromatin. Intranuclear vacuoles or pseudoinclusions are common and have been shown to label with p62/SQSTM1 antibodies [106]D.
- Transitional Subtype: This common variant exhibits features of both syncytial and fibroblastic types, often demonstrating prominent whorl formation [87][90]C. Interestingly, the transitional subtype has been associated with higher proliferation indices compared to other benign variants [100]D.
Immunohistochemical Profile
Immunohistochemistry is essential for confirming the arachnoidal origin and excluding mimics like or [90]C[92]C.
- SSTR2 and Neuroendocrine Markers: Somatostatin receptor 2 (SSTR2) is a highly sensitive marker for meningioma [98]D. Despite expressing SSTR2, meningiomas do not show evidence of neuroendocrine differentiation; they are consistently negative for chromogranin A, chromogranin B, synaptophysin, and secretagogin [98]D.
- Proliferation Markers: The Ki-67 proliferation index (PI) and mitotic count are the primary markers of biological activity. Digital analysis of Ki-67 "hotspots" (areas of maximal staining) is more prognostic for recurrence-free survival than average slide counts [107]D. Higher Ki-67 levels and mitotic counts correlate strongly with increased WHO grade [100]D.
- Diagnostic Surrogates:
- Merlin (NF2): Loss of Merlin expression (the protein product of the NF2 gene) is seen in approximately 90% of meningiomas with NF2 alterations, though its reliability as a sole surrogate for NF2 mutation is debated [50]D[52]D.
- MTAP: Loss of MTAP expression serves as a reliable surrogate for CDKN2A homozygous deletion, a marker of high-grade behavior and poor prognosis [62].
- H3 K27me3: The loss of trimethylation at Lysine 27 of Histone 3 (H3 K27me3) is an emerging prognostic marker associated with increased risk of recurrence [97]D.
Molecular Stratification
Recent advancements have proposed a molecular classification system that may supersede traditional WHO grading in predictive power. This system categorizes meningiomas into four molecular groups (MG) based on IHC markers: MG1 (S100B), MG2 (SCGN), MG3 (ACADL), and MG4 (MCM2) [101]D. Additionally, the absence of intracellular alkaline phosphatase activity, detectable via the AlkaPhos fluorescent probe, correlates with 1p deletion, a known driver of recurrence regardless of tumor grade [103]D.
| Marker | Clinical/Pathological Significance | Evidence Level |
|---|---|---|
| SSTR2 | Highly sensitive diagnostic marker for meningothelial origin | [98]D |
| Ki-67 (MIB-1) | Proliferation index; hotspots correlate with recurrence risk | [100]D[107]D |
| MTAP | Loss indicates CDKN2A homozygous deletion (High Grade) | [62] |
| H3 K27me3 | Loss is associated with poor prognosis and recurrence | [97]D |
| Merlin | Loss suggests NF2 gene alteration (22q loss) | [50]D[52]D |
| p62/SQSTM1 | Labels intranuclear vacuoles; involved in cellular growth | [106]D |
| AlkaPhos | Loss of activity correlates with 1p deletion | [103]D |
Immunohistochemistry and Molecular Markers
- ▸SSTR2 is the most sensitive and specific diagnostic marker for meningioma and forms the basis for DOTATATE PET imaging.
- ▸TERT promoter mutations and CDKN2A/B homozygous deletions are molecular 'grade-jumpers' that mandate a WHO Grade 3 classification regardless of histology.
- ▸The Ki-67/MIB-1 labeling index is a critical predictor of recurrence, with thresholds of 5-10% often triggering more intensive postoperative surveillance.
The diagnostic and prognostic landscape of meningioma has shifted from purely morphological assessment to an integrated approach combining immunohistochemistry (IHC) and molecular profiling. This evolution is driven by the need to identify tumors with aggressive biological behavior that may appear histologically benign but carry a high risk of recurrence [116][117]. IHC markers serve two primary roles: confirming the arachnoid cell origin and providing surrogate data for underlying genetic alterations that dictate clinical outcomes [62][101]D.
Diagnostic Immunohistochemical Markers
Confirmation of meningioma diagnosis relies on a panel of markers that reflect the tumor's origin from arachnoid cap cells. While Vimentin and Epithelial Membrane Antigen (EMA) have historically been the standard, they lack high specificity [120]C.
- Somatostatin Receptor 2 (SSTR2): This is currently the most sensitive and specific marker for meningioma [98]D. SSTR2 expression is nearly universal across all WHO grades and histological subtypes. Beyond diagnosis, SSTR2 serves as the biological basis for 68Ga-DOTATATE PET/CT imaging, where the maximum standardized uptake value (SUV-max) correlates with tumor grade and RNA-based risk classifications [126]D.
- EMA and Vimentin: Most meningiomas show diffuse positivity for Vimentin and focal, often membranous, positivity for EMA [120]C. These are useful but can be positive in other mesenchymal or epithelial tumors.
- Differential Diagnosis Markers: IHC is critical in distinguishing meningiomas from mimics. For instance, Rosai-Dorfman disease (a lymphoproliferative disorder) may mimic meningioma radiologically but is identified by S100 and CD68 positivity with characteristic emperipolesis [38]C. Similarly, Myeloid Sarcoma of the skull base can mimic en plaque meningioma but is distinguished by markers like MPO and CD34 [114]C.
- Neuroendocrine Markers: Despite expressing SSTR2, meningiomas do not exhibit true neuroendocrine differentiation. They are typically negative for Chromogranin A, Synaptophysin, and Secretagogin [98]D.
Proliferation Markers: Ki-67 and MIB-1
The Ki-67 proliferation index (PI), typically measured using the MIB-1 antibody, is the most widely used IHC marker for predicting recurrence [110][117]. It reflects the percentage of tumor cells in the active phases of the cell cycle.
While the WHO grading system relies heavily on mitotic count, the Ki-67 index provides an independent measure of growth potential. Higher Ki-67 levels are strongly associated with higher WHO grades and decreased progression-free survival (PFS) [100]D[117]. However, optimal cutoffs remain a subject of debate due to inter-institutional variability. Common thresholds used to define "high-risk" tumors include 4%, 5%, and 9% [123]D[124]D[101]D. In atypical meningiomas (WHO Grade 2), a Ki-67 index above 7% to 10% is often used to identify patients at higher risk for progression [8].
Molecular Markers for Grading and Prognosis
Recent updates to classification systems emphasize molecular markers that override histological features in determining WHO grade [116].
- TERT Promoter Mutation: Mutations in the TERT promoter (specifically C228T and C250T) are associated with aggressive clinical behavior and are now sufficient to classify a meningioma as WHO Grade 3, regardless of histological appearance [116][72]C. These mutations lead to telomerase reactivation and cellular immortality.
- CDKN2A/B Homozygous Deletion: The loss of the CDKN2A/B locus on chromosome 9p21 is a hallmark of malignant progression. Like TERT mutations, its presence warrants a WHO Grade 3 designation [62][113].
- MTAP as a Surrogate: Because molecular testing for CDKN2A is expensive, IHC for 5'-methylthioadenosine phosphorylase (MTAP) is used as a surrogate. Loss of MTAP expression highly correlates with CDKN2A homozygous deletion [62].
- H3 K27me3 Loss: The loss of trimethylation at Lysine 27 of Histone 3 (H3 K27me3) is an emerging epigenetic marker. Its loss via IHC is associated with a higher risk of recurrence and poorer overall survival, particularly in tumors that otherwise appear low-grade [97]D.
- Progesterone and Estrogen Receptors: Most meningiomas are Progesterone Receptor (PR) positive, which generally correlates with a more benign course. Conversely, Estrogen Receptor (ER) expression is rare (<20%). Interestingly, the use of Dexamethasone to treat peritumoral edema has been shown to suppress already low ER levels in these tumors [119]D.
Integrated Molecular Risk Stratification Protocol
Clinicians use an integrated approach to stratify recurrence risk and determine the need for adjuvant therapy [101]D[125]D.
Step 1: Histological Grading → Assess mitotic count and morphological subtypes (e.g., chordoid, clear cell). Step 2: Proliferation Assessment → Perform Ki-67/MIB-1 IHC. If >5-10%, increase surveillance frequency [117][124]D. Step 3: Molecular Screening → Test for TERT promoter mutations and CDKN2A/B deletion (or MTAP IHC) in all Grade 2 tumors or aggressive Grade 1 tumors [62][116]. Step 4: Epigenetic/Copy Number Analysis → Evaluate for 1q gain or H3 K27me3 loss, which are associated with poor response to stereotactic radiosurgery (SRS) and higher recurrence rates [125]D[97]D. Step 5: Immunotherapy Markers → Assess PD-L1 expression. PD-L1 positivity is prevalent in high-risk molecular groups (e.g., MenG C) and may predict a "hyperaggressive" phenotype [65][121]D.
Radiomics and Machine Learning
Given the invasive nature of biopsy, there is increasing interest in using MRI-derived radiomics and machine learning to predict molecular status non-invasively. Models integrating T1-weighted contrast-enhanced and T2-weighted images can predict the Ki-67 index with high sensitivity and specificity, potentially guiding surgical planning before the first incision [111][112][123]D.
| Marker | Utility | Clinical Significance |
|---|---|---|
| SSTR2 | Diagnostic | Highly specific for arachnoid origin; correlates with DOTATATE PET uptake [98]D[126]D. |
| Ki-67 (MIB-1) | Prognostic | Thresholds of >5-10% predict high recurrence risk and shorter PFS [117][124]D. |
| MTAP | Molecular Surrogate | Loss of expression indicates CDKN2A/B homozygous deletion [62]. |
| H3 K27me3 | Epigenetic | Loss of expression correlates with increased malignancy and poor prognosis [97]D. |
| PR | Prognostic | Progesterone receptor positivity is generally associated with lower-grade tumors [119]D. |
| PD-L1 | Predictive | High expression in MenG C tumors identifies a hyperaggressive subgroup [121]D. |
| Molecular Alteration | Detection Method | Clinical Impact |
|---|---|---|
| TERT Promoter Mutation | Sequencing (C228T/C250T) | Automatically defines WHO Grade 3; high recurrence risk [116][72]C. |
| CDKN2A/B Deletion | FISH / NGS / MTAP IHC | Automatically defines WHO Grade 3; associated with malignant transformation [62][113]. |
| 1q Gain | Chromosomal Microarray | Associated with poor tumor control after radiosurgery [125]D. |
Clinical Presentation and Neurological Manifestations
- ▸Meningioma symptoms are primarily location-dependent and typically progress over months to years, with seizures affecting 30% of symptomatic patients.
- ▸Peritumoral brain edema (PTBE) is a critical prognostic factor for preoperative seizures and postoperative complications.
- ▸Olfactory groove meningiomas frequently present with subtle cognitive and behavioral changes that may precede physical neurological deficits.
Meningiomas are the most common primary central nervous system (CNS) neoplasms, representing approximately 40% of all cases, with a peak prevalence in the fifth and sixth decades of life [131][136]D. Because these tumors typically arise from arachnoid cap cells and grow slowly, clinical manifestations often remain occult for years, frequently coming to light as incidental findings on neuroimaging or through the gradual onset of location-specific deficits [131][139]C. The clinical presentation is dictated primarily by the tumor's anatomical site, its relationship with adjacent neurovascular structures, and the degree of associated peritumoral brain edema (PTBE) [130][141]D.
Presenting Symptoms
The timeline of symptom progression in meningioma is typically indolent, spanning months to years, though acute presentations can occur in the setting of intratumoral hemorrhage (ITH) or rapid expansion of PTBE [132][135].
- Seizures: New-onset focal or generalized seizures are a hallmark presentation, affecting approximately 30% of symptomatic preoperative patients [136]D. In the pediatric population, seizures are a particularly frequent presenting feature [11][74]D. The risk of epilepsy is strongly correlated with the presence of peritumoral edema, which alters the local cortical microenvironment and lowers the seizure threshold [130][136]D.
- Headache: Often the most common non-specific symptom, headaches result from mass effect, traction on dural structures, or elevated intracranial pressure (ICP) [67]C[132].
- Cognitive and Behavioral Changes: Patients with tumors in the frontal region, particularly olfactory groove meningiomas (OGMs), may present with subtle personality shifts, executive dysfunction, or affective disorders that are often misdiagnosed as primary psychiatric conditions [128].
- Visual and Cranial Nerve Deficits: Parasellar and sphenoid wing tumors frequently present with progressive visual field loss, diplopia, or proptosis [134]C[144]D.
Neurological Examination Findings
A systematic neurological examination is essential to localize the lesion and assess the functional impact of the tumor. The examination should be organized by functional systems:
Step-by-Step Clinical Assessment Protocol
- Mental Status and Frontal Release Signs: Evaluate for executive dysfunction, apathy, or disinhibition, especially in subfrontal or parasagittal lesions [128]. Check for primitive reflexes (e.g., grasp, snout).
- Cranial Nerve (CN) Survey:
- CN I: Test olfaction; anosmia is a classic finding in OGMs [137].
- CN II, III, IV, VI: Perform formal visual field testing and extraocular movement assessment. Spheno-orbital meningiomas (SOMs) often cause proptosis in 94.2% of cases and diplopia in 44.2% [144]D.
- CN VIII: Assess for sensorineural hearing loss, which may indicate an ectopic meningioma in the attic or middle ear [120]C.
- Motor and Sensory Systems: Assess for contralateral hemiparesis or sensory loss, which may indicate a convexity or parasagittal tumor compressing the motor/sensory strip.
- Reflexes and Gait: Hyperreflexia and a spastic gait may suggest spinal cord compression or significant mass effect on the motor pathways [127].
Phenotypic and Anatomical Variants
Meningiomas exhibit diverse clinical phenotypes based on their location and rare histological subtypes.
| Variant | Key Clinical Features | Frequency/Context |
|---|---|---|
| Olfactory Groove (OGM) | Anosmia, Foster Kennedy syndrome (ipsilateral optic atrophy, contralateral papilledema), and cognitive decline [128][137]. | 4.5–18% of intracranial meningiomas [137] |
| Spheno-orbital (SOM) | Progressive proptosis, orbital pain, and visual impairment [144]D. | Rare; involves the sphenoid wing and orbit |
| Intrasellar | Mimics pituitary adenoma; presents with visual field defects and pituitary dysfunction [134]C. | Rare; requires differentiation from adenomas |
| Spinal (Pediatric) | Back pain, progressive myelopathy, and gait disturbances [127]. | Rare in children; high recurrence risk |
| Sylvian Fissure | Presents with seizures and headaches; notably lacks dural attachment [67]C. | Extremely rare; often WHO Grade 2 |
| Xanthomatous | Characterized by meningothelial cells with foamy, eosinophilic cytoplasm [133]. | Rare histological subtype |
Red Flags and Urgent Manifestations
While most meningiomas are benign, certain clinical scenarios require immediate intervention:
- Venous Intracranial : Compression or invasion of the dural venous sinuses (e.g., superior sagittal sinus) can lead to severe intracranial hypertension, papilledema, and rapid visual loss [129].
- Intratumoral Hemorrhage (ITH): Although rare, ITH can cause sudden neurological deterioration, severe headache, and coma [132]. Risk factors include age, specific locations, and histological grade [132].
- Status Epilepticus: Refractory seizures in meningioma patients are often resistant to standard anti-seizure medications (ASMs) and may indicate aggressive tumor growth or worsening edema [136]D.
- Brain Invasion: Clinical signs of rapid focal progression may suggest brain invasion, a criterion for WHO Grade 2 (atypical) status, which is associated with higher recurrence rates [142]D.
Atypical and Ectopic Presentations
Meningiomas may occasionally present in extra-axial locations or with unusual systemic findings. Primary pulmonary meningiomas can appear as incidental lung nodules, often asymptomatic and discovered during routine thoracic imaging [139]C. Ectopic intracranial meningiomas may occur in the middle ear or attic, presenting as unilateral sensorineural hearing loss [120]C. In rare cases, meningiomas in the temporoparietal junction have been associated with vestibular epilepsy, characterized by episodic vertigo and nystagmus [95]C.
Clinicians must also be aware of the high recurrence risk in atypical (WHO Grade 2) and malignant (WHO Grade 3) variants. These aggressive tumors often present with more rapid symptom onset and are associated with higher Ki-67 proliferation indices (thresholds of ≥4% or ≥5%) [123]D[124]D[138]C.
| Feature | Spheno-orbital (SOM) [144]D | Intrasellar [134]C | Anterior Clinoidal (ACM) [71]C |
|---|---|---|---|
| Primary Symptom | Proptosis (94.2%) | Visual Deficits | Visual Loss |
| Secondary Symptom | Diplopia (44.2%) | Pituitary Dysfunction | Cranial Nerve Palsy |
| Visual Loss Rate | 40.4% | High | Variable |
| Surgical Challenge | Orbital involvement | Pituitary compression | Vascular encasement |
Diagnostic Imaging and Radiology
- ▸MRI with gadolinium contrast is the definitive imaging modality, characterized by homogeneous enhancement and the 'dural tail sign'.
- ▸[⁶⁸Ga]Ga-DOTATATE PET/CT leverages SSTR2 expression for high-specificity diagnosis and recurrence monitoring.
- ▸Radiomics and ADC values are increasingly used to non-invasively predict WHO grade, Ki-67 index, and tumor consistency.
Imaging is the cornerstone of meningioma diagnosis, providing critical information on tumor location, vascular involvement, and potential malignancy [150]D. While many meningiomas are discovered incidentally, their radiographic appearance guides the decision between conservative observation and surgical intervention [24]D. Magnetic resonance imaging (MRI) remains the gold standard due to its superior soft-tissue contrast, while computed tomography (CT) provides essential data regarding bone invasion and calcification [150]D[154]D.
Magnetic Resonance Imaging (MRI)
MRI is the primary modality for characterizing meningiomas. These tumors typically appear isointense to hypointense on T1-weighted images and isointense to hyperintense on T2-weighted images [153]D. Following the administration of gadolinium (e.g., 0.1 mmol/kg), meningiomas usually demonstrate robust, homogeneous enhancement [154]D. A hallmark radiographic feature is the "dural tail sign," representing reactive thickening of the adjacent dura mater, which is often used to differentiate meningiomas from other extra-axial lesions [11][157]D.
Advanced MRI sequences provide deeper insights into tumor biology:
- Fluid-Attenuated Inversion Recovery (FLAIR): Essential for identifying peritumoral brain edema (PTBE), which appears as hyperintensity in the adjacent white matter [141]D[158]D. PTBE is a frequent finding and may indicate more aggressive behavior or the expression of molecular markers like FOXC1 [141]D.
- Diffusion-Weighted Imaging (DWI): The apparent diffusion coefficient (ADC) is used to estimate tumor cellularity. Lower ADC values (normalized ADC) are often associated with higher-grade (WHO Grade 2/3) meningiomas [154]D[156]D.
- High-Resolution (HR) T2-weighted MRI: In skull base tumors, HR T2 is superior for depicting the cisternal paths of cranial nerves (CNs) displaced by the mass, though tractography may be required for complex reconstructions [146]C.
- Synthetic MRI (SyMRI): Emerging relaxometry techniques using SyMRI can predict tumor consistency (soft vs. hard) by measuring T1 and T2 relaxation times, which is vital for preoperative surgical planning [155]D.
Computed Tomography (CT)
CT is complementary to MRI, particularly for evaluating the effect of the tumor on the skull. Meningiomas are typically hyperdense on non-contrast CT due to their high cellularity [114]C. CT is the modality of choice for detecting calcifications, which occur in approximately 20–25% of cases, and hyperostosis, a reactive thickening of the bone adjacent to the tumor [114]C[150]D. In cases of "en plaque" meningiomas, CT is essential to visualize the extensive bone involvement that may be missed on standard MRI [114]C.
Nuclear Medicine: SSTR PET/CT
Meningiomas characteristically overexpress somatostatin receptor 2 (SSTR2). This biological feature allows for highly specific imaging using [⁶⁸Ga]Ga-DOTATATE PET/CT [149]C[150]D. This modality is particularly useful in:
- Differentiating residual or recurrent tumor from post-operative scarring or radiation necrosis [150]D.
- Delineating tumor extent in complex anatomical regions like the cavernous sinus or optic nerve sheath [149]C.
- Detecting rare extracranial metastases, which most commonly spread to the lungs, bone, and liver [29]D.
Advanced Radiomics and Predictive Modeling
Recent advances in machine learning and radiomics allow for the non-invasive prediction of tumor grade and growth risk from standard imaging [152]D[153]D. Radiomic features extracted from the brain-tumor interface (BTI)—specifically a 4 mm region surrounding the tumor—have shown high accuracy in predicting the Ki-67 proliferation index and brain invasion [124]D[142]D. Furthermore, a single contrast-enhanced MRI scan can now be used with convolutional neural networks to predict whether a meningioma is likely to remain stable or grow, potentially reducing the need for frequent serial imaging in low-risk patients [152]D.
Specialized Anatomical Considerations
- Skull Base: Imaging must evaluate the involvement of critical vasculature. Contrast-enhanced MRI and CT angiography (CTA) are used to determine if the internal carotid artery (ICA) is encased, displaced, or narrowed [78]D. Foramen magnum tumors require careful assessment of the median medullary perforators using gadolinium-enhanced sequences to avoid ischemic complications during resection [148]C.
- Spinal Meningiomas: These are typically intradural extramedullary (IDEM) lesions. MRI is used to classify them as ventral or dorsal/lateral, with ventral lesions often presenting with larger sagittal diameters and more complex surgical requirements [64].
- Ectopic Locations: Meningiomas can rarely occur outside the cranial vault, such as in the middle ear (attic), presenting as a mass causing unilateral hearing loss [120]C.
Diagnostic Algorithm for Suspected Meningioma
- Step 1: Initial Detection. Non-contrast CT or MRI (often performed for headache or seizures) [11][114]C.
- Step 2: Characterization. Multi-parametric MRI including T1-weighted contrast-enhanced (T1CE), T2, and FLAIR sequences to assess dural attachment and edema [153]D[157]D.
- Step 3: Advanced Assessment. DWI/ADC for grading and SyMRI for consistency if surgery is planned [154]D[155]D.
- Step 4: Specialized Imaging. [⁶⁸Ga]Ga-DOTATATE PET/CT if the diagnosis is uncertain or for recurrent disease [149]C[159]D.
- Step 5: Risk Stratification. Application of tools like the IMPACT tool or radiomic models to determine the frequency of follow-up [24]D[152]D.
| Feature | Imaging Modality | Clinical Significance |
|---|---|---|
| Dural Tail Sign | MRI (T1CE) | Suggests meningioma; represents reactive dural thickening [157]D |
| Hyperostosis | CT | Indicates bone invasion or reactive bone growth [114]C |
| Peritumoral Edema | MRI (FLAIR) | Associated with FOXC1 expression and higher morbidity [141]D |
| Low ADC Value | MRI (DWI) | Correlates with higher WHO grade and increased cellularity [154]D |
| SSTR2 Uptake | DOTATATE PET | Highly specific for meningothelial cells; aids in recurrence detection [149]C |
| PVS Dilation | MRI | Indicates glymphatic disruption in the perivascular space [151]D |
Differential Diagnosis
- ▸Solitary fibrous tumor (SFT) is the most critical mimic due to its aggressive clinical course and the need for STAT6 immunohistochemistry for definitive identification [162, 164].
- ▸Advanced imaging such as MRS (myoinositol peak) and SSTR PET (somatostatin receptor targeting) provides high specificity in differentiating meningiomas from lymphomas and SFTs [173, 180].
- ▸Approximately 2% of presumed meningiomas are actually mimics, necessitating a high index of suspicion when atypical features like bone erosion or disproportionate edema are present [189].
Meningiomas are the most common primary central nervous system (CNS) neoplasms, representing approximately 40% of all brain tumors [165]D. While their radiological appearance is often characteristic, approximately 2% of dural-based lesions initially suspected to be meningiomas are revealed to be other neoplastic or non-neoplastic entities upon histopathological examination [189]D. Differentiating these mimics is critical because strategies vary significantly, ranging from observation to aggressive multimodal therapy [166]D[178]D.
(SFT)
Formerly classified separately as hemangiopericytoma, solitary fibrous tumors (SFT) are the most challenging mimics of meningioma [162][168]D. Unlike typically benign meningiomas, SFTs exhibit aggressive local behavior and high rates of post-resection recurrence and hematogenous metastasis [162][178]D.
- Radiological Differentiation: SFTs often lack the intratumoral calcification common in meningiomas and frequently present with more heterogeneous enhancement and internal flow voids [162][189]D. On Magnetic Resonance Spectroscopy (MRS), the presence of a myoinositol peak is highly specific for SFT, whereas meningiomas typically show an alanine peak [180]D.
- Diffusion Weighted Imaging (DWI): Apparent diffusion coefficient (ADC) histogram analysis can assist in differentiation; SFTs often demonstrate different ADC percentile values compared to atypical meningiomas [185]D.
- Immunohistochemistry (IHC): This is the definitive diagnostic tool. SFTs are characterized by STAT6 nuclear expression (due to NAB2-STAT6 fusion) and are typically negative for CD13 [164]C[186]D[188]D. Conversely, meningiomas are generally STAT6-negative and frequently express CD13 and Epithelial Membrane Antigen (EMA) [186]D.
Primary Dural Lymphomas
Several types of lymphoma can mimic the "en plaque" growth pattern of meningiomas, including B-cell lymphoma, Marginal Zone MALT-type lymphoma, and rarely, Acute Lymphoblastic Leukemia (ALL) [169]C[170]C[177]C.
- Clinical Presentation: Lymphomas may present with rapid neurological decline, seizures, and significant peritumoral edema that is often disproportionate to the lesion size [169]C[177]C.
- Imaging Features: While they may exhibit a "dural tail sign" similar to meningiomas, lymphomas often show restricted diffusion on DWI and intense uptake on 18F-FDG PET [173]D[177]C. In contrast, meningiomas are better characterized using 68Ga-SSTR PET ligands, which target somatostatin receptors [173]D.
Anatomical Mimics by Location
Specific intracranial compartments harbor unique differential considerations:
- Cavernous Sinus: While meningiomas are common here, the differential includes pituitary adenomas, schwannomas, , sarcoidosis, and [176]D. Percutaneous transforamen ovale biopsy may be required when imaging is inconclusive [171]C.
- Spheno-orbital Region: Differentiating meningioma from other lesions of the greater wing of the sphenoid requires assessing bone response. Meningiomas typically cause hyperostosis, whereas mimics like metastatic carcinoma or sarcoidosis may cause frank bone erosion or osteolysis [175]D.
- Spinal Canal: Intradural extramedullary meningiomas must be distinguished from schwannomas and metastatic disease. Advanced techniques like picosecond infrared laser mass spectrometry (PIRL-MS) are being developed for rapid (10-second) intraoperative differentiation [181]D.
Rare Mimics and Collision Tumors
- Rosai-Dorfman Disease (RDD): This benign histiocytic proliferative disorder can present as a dural-based mass mimicking meningioma on CT and MRI, requiring histology for definitive diagnosis [191]C.
- Collision Tumors: In rare instances, two histologically distinct tumors (e.g., SFT and meningioma, or meningioma and B-cell lymphoma) can occur synchronously in the same anatomic location [163][164]C.
- Mesenchymal Tumors: FET-CREB fusion-positive mesenchymal tumors represent a distinct epigenetic subgroup that can mimic meningeal neoplasms, primarily in pediatric populations [187]D.
Diagnostic Algorithm for Dural-Based Lesions
Step 1: Conventional Neuroimaging → Perform MRI with and without gadolinium. Evaluate for "red flags" such as bone erosion, lack of calcification, or disproportionate edema [189]D.
Step 2: Advanced MRI Sequences → Utilize DWI/ADC to assess cellularity and MRS to look for the myoinositol peak (suggestive of SFT) or alanine peak (suggestive of meningioma) [180]D[185]D.
Step 3: Nuclear Medicine → If the diagnosis remains uncertain, order 68Ga-DOTATATE (SSTR) PET. High uptake is strongly suggestive of meningioma, whereas 18F-FDG PET is more sensitive for lymphoma or high-grade malignancy [173]D.
Step 4: Tissue Acquisition and IHC → Obtain tissue via biopsy or resection. Perform a panel including EMA, STAT6, and CD13 to confirm the molecular identity [186]D[188]D.
| Feature | Meningioma | Solitary Fibrous Tumor (SFT) | Dural Lymphoma |
|---|---|---|---|
| Key MRI Finding | Dural tail, calcification common [189]D | Heterogeneous, flow voids [162] | Intense enhancement, restricted diffusion [177]C |
| MRS Peak | Alanine | Myoinositol [180]D | Lipid/Lactate |
| PET Tracer | 68Ga-SSTR (High) [173]D | Variable | 18F-FDG (High) [173]D |
| IHC Markers | EMA+, CD13+, STAT6- [186]D | STAT6+, CD13- [164]C[186]D | CD20+ (if B-cell) [170]C |
| Bone Effect | Hyperostosis [175]D | Erosion/Destruction | Usually none |
| Behavior | Typically benign (WHO Grade 1) | Aggressive, high recurrence [178]D | Systemic or localized |
Surgical Management and Techniques
- ▸The Simpson Grading system remains the gold standard for defining the extent of resection and predicting recurrence risk.
- ▸Hypofractionated stereotactic radiosurgery (HSRS) is superior to single-session SRS for meningiomas larger than 8 cc to reduce peritumoral edema.
- ▸Anterior clinoidectomy is a critical technical step for managing clinoidal meningiomas to achieve early optic nerve decompression.
The primary objective of surgical intervention for is achieving maximal safe resection while preserving neurological function. Surgery remains the reference treatment for symptomatic or growing tumors [196]. The extent of resection (EOR) is the most significant predictor of long-term recurrence, particularly in cases where complete removal is hindered by critical neurovascular structures [115]. requires a multidisciplinary approach, integrating advanced imaging, microsurgical techniques, and intraoperative adjuncts to optimize outcomes.
Step 1: Preoperative Planning and Risk Stratification
Initial management begins with high-fidelity simulation and risk assessment. For complex skull base lesions, such as sphenoid wing meningiomas, 3D-printed models and virtual reality (VR) are utilized to quantify the brain retraction distance (BRD) required for exposure, as excessive retraction is a primary driver of brain retraction injury (BRI) [198]D[200]D. Radiomic analysis of preoperative MRI (T1, T2, FLAIR, ADC) is increasingly used to predict tumor grade (Grade 1 vs. Grade 2), which informs the aggressiveness of the surgical approach [153]D. In pediatric patients, clinicians must account for a higher risk of recurrence and distinct histopathology compared to adults [127]. If the patient presents with seizures, perioperative anti-seizure medication (ASM) is initiated, though specific protocols vary [11].
Step 2: Selection of Surgical Approach
The choice between traditional transcranial approaches (TCA) and minimally invasive surgical (MIS) techniques depends on tumor location and size.
- Anterior Skull Base Meningiomas (ASBM): Meta-analysis indicates no significant difference in Gross Total Resection (GTR) rates between TCA and MIS, though MIS may offer faster recovery [193]. For olfactory groove meningiomas, approaches include pterional, subfrontal, or endoscopic endonasal [137].
- Anterior Clinoidal Meningiomas (ACM): These require anterior clinoidectomy (AC) to enable early optic nerve decompression and tumor devascularization [192]. A "2-stage 4 by 4 step" concept is recommended for safe clinoid removal [192].
- Cerebellopontine Angle (CPA): The fully endoscopic retrosigmoid approach (FERA) provides panoramic visualization of deep recesses, potentially improving facial nerve and hearing preservation compared to traditional microscopic approaches [86].
- Optic Nerve Sheath Meningioma (ONSM): While radiotherapy is standard, the Endoscopic Endonasal Approach (EEA) is a viable minimally invasive alternative for optic nerve decompression to restore vision [194].
Step 3: Intraoperative Resection and Monitoring
During resection, the Simpson Grading System is used to categorize the EOR (see Table 1). For Grade 2 and 3 meningiomas, which have high recurrence rates, Photodynamic Therapy (PDT) may be employed. Talaporfin sodium 2 mg/kg IV is administered 22–26 hours prior to surgery; intraoperative laser irradiation then generates selective cytotoxicity beyond the visible margins [76]D. To distinguish neoplastic from non-neoplastic tissue in real-time, Confocal Laser Endomicroscopy (CLE) provides cellular-level visualization [99]D. For tumors involving the internal carotid artery (ICA), blood flow reconstruction techniques are utilized to maintain cerebral perfusion during radical resection [78]D.
Step 4: Management of Large and Complex Lesions
For large meningiomas (>8 cc), single-session stereotactic radiosurgery (SSRS) carries a higher risk of radiation-induced toxicity. Hypofractionated stereotactic radiosurgery (HSRS) is preferred as it delivers high doses in multiple fractions, minimizing peritumoral edema [2]. In cases of subtotal resection (STR), the surface area of dural attachment of the remnant is a key predictor of future progression [157]D.
Step 5: Postoperative Evaluation and Transition
Postoperative complications are classified using the Therapy-Disability-Neurology (TDN) grading system, which accounts for disabling neurologic deficits often missed by traditional scales [19]D. If orbital involvement was present, reconstruction is critical for lesions that have not yet caused bony remodeling to prevent delayed pulsatile enophthalmos [197]C. Long-term follow-up (up to 15 years) is essential, as recurrence dynamics can shift significantly beyond the first decade [115].
| Grade | Definition | Recurrence Risk |
|---|---|---|
| Grade I | Macroscopic GTR including dural attachment and abnormal bone | Lowest |
| Grade II | Macroscopic GTR with coagulation of dural attachment | Low |
| Grade III | Macroscopic GTR without dural coagulation or resection | Intermediate |
| Grade IV | Subtotal resection (STR) | High |
| Grade V | Simple decompression or biopsy | Highest |
| Drug | Dose | Route | Timing/Duration | Key ADR | Evidence Level |
|---|---|---|---|---|---|
| Talaporfin Sodium | 2 mg/kg | IV | 22–26h pre-laser | Photosensitivity | 5 [76]D |
| Azacitidine | Investigational | N/A | Refractory cases | Myelosuppression | 5 [122]D |
| Levetiracetam | Varies | IV/PO | Perioperative | Somnolence | 2b [11] |
Radiation Therapy and Radiosurgery
- ▸Hypofractionated SRS (e.g., 25 Gy in 5 fractions) is superior to single-session SRS for meningiomas >8 cc, as it significantly reduces the risk of peritumoral edema.
- ▸(68)Ga-DOTATATE PET/CT is a critical adjunct to MRI for radiation planning, identifying residual tumor tissue that expresses SSTR2.
- ▸Adjuvant radiotherapy is mandatory for WHO Grade 2 and 3 meningiomas to improve local control, typically using doses of 54-60 Gy.
Radiation therapy (RT) and stereotactic radiosurgery (SRS) serve as cornerstones in the of , particularly when surgical resection is incomplete, the tumor is located in surgically inaccessible regions, or the lesion exhibits aggressive WHO Grade 2 or 3 histology [196][28]D. While gross total resection (GTR) remains the primary goal, adjuvant or primary radiation is increasingly utilized to achieve long-term local control (LC) and preserve neurological function [83]D[213].
Step 1: Initial Assessment and Severity Classification
Management begins with a multidisciplinary evaluation to determine the tumor's grade, volume, and proximity to critical structures. For patients requiring adjuvant radiation, (68)Ga-DOTATATE PET/CT is recommended to supplement MRI, as it targets somatostatin receptor 2 (SSTR2) which is almost universally expressed in meningiomas [202]. This imaging modality can detect residual disease not discernible on standard MRI, allowing for more precise dose-escalation and target volume delineation (Level 1c) [202].
- Small/Medium Tumors (<8 cc or <3 cm): Typically candidates for single-session SRS (SSRS) [213][83]D.
- Large Tumors (>8 cc or >3 cm): Require hypofractionated stereotactic radiosurgery (HSRS) or fractionated radiotherapy (FSRT) to minimize the risk of radiation-induced toxicity and peritumoral edema (PTE) [2][210].
- High-Grade (WHO Grade 2/3): Adjuvant fractionated RT is standard regardless of the extent of resection due to high recurrence rates [69][28]D.
Step 2: Selection of Radiation Modality and Dosing
The choice between SSRS, HSRS, and FSRT depends on tumor volume and location.
Single-Session Stereotactic Radiosurgery (SSRS): For sporadic, small-to-medium meningiomas, Gamma Knife or Linac-based SRS is highly effective. A median margin dose of 14-16 Gy is standard for benign (WHO Grade 1) lesions [213][83]D. In a 25-year cohort study, SSRS achieved excellent progression-free survival (PFS) with a median margin dose of 15 Gy [213]. For tumors causing , a single procedure may target the tumor with 12-13.4 Gy while simultaneously delivering a higher dose (e.g., 88.9 Gy) to the trigeminal nerve to alleviate pain [214][211].
Hypofractionated Stereotactic Radiosurgery (HSRS): For larger tumors (>8 cc), HSRS (e.g., 25 Gy in 5 fractions) is preferred over SSRS [2][201]. HSRS delivers a high biological dose while allowing for normal tissue repair between fractions, significantly reducing the rates of symptomatic peritumoral edema compared to SSRS (Level 2a) [2]. In optic nerve sheath meningiomas (ONSMs), HSRS with 25 Gy in 5 fractions has shown promise in preserving visual function and achieving local control [201][209].
Fractionated Radiotherapy (FSRT) and Proton Therapy: FSRT is utilized for large skull base lesions or high-grade tumors. Standard dosing is 50.4-59.4 Gy delivered in 1.8 Gy fractions [77]D[28]D. Proton therapy (PT) is an emerging modality with unique ballistic properties (the Bragg peak) that reduce the integral dose to healthy brain tissue [207][160]D. PT is particularly relevant in pediatric populations to minimize long-term sequelae [77]D.
Step 3: Management of High-Risk and Complex Cases
WHO Grade 2 and 3 Meningiomas: These aggressive variants require higher doses, often up to 60 Gy in fractionated regimens [28]D. Despite modern techniques, these patients often experience lower health-related quality of life (HRQoL) due to both tumor progression and treatment morbidity [204]. Adjuvant RT is critical after subtotal resection (STR) to delay recurrence [69].
Neurofibromatosis Type 2 (NF2): Managing NF2-associated meningiomas is complex due to the high tumor burden. Gamma Knife SRS is effective, with 3-year survival rates reaching 100%, though long-term monitoring is essential as these patients often require multiple interventions over their lifetime [203][205].
Step 4: Monitoring and Management of Complications
Patients must be monitored with serial MRI for both tumor response and adverse radiation effects (ARE).
- Peritumoral Edema (PTE): More common in large tumors treated with SSRS [2].
- Brain Radionecrosis (BRN): Risk increases with higher RBE-weighted doses and dose-averaged linear energy transfer (LETd) in proton therapy [160]D.
- SMART Syndrome: Stroke-like migraine attacks after radiation therapy (SMART) can occur with a latency of 5 months to 35 years post-irradiation [212]. Symptoms include migraines, seizures, and stroke-like deficits [212].
- Molecular Prognostics: Presence of 1q gain has been identified as a negative prognostic factor, correlating with poorer PFS after SRS [125]D.
Step 5: Treatment Failure and Re-irradiation
In cases of local recurrence after initial RT, re-irradiation is a viable but high-risk option. Approximately 56% of European centers consider re-irradiation for recurrent meningiomas [159]D. Repeated SRS can be used for high-grade recurrences, though it requires careful dose planning to avoid cumulative toxicity [85]D.
| Modality | Typical Dose/Fractionation | Primary Indication | Evidence Level |
|---|---|---|---|
| Single-Session SRS | 14–16 Gy (Margin) | Small tumors (<8 cc), skull base | 2b [213][83]D |
| Hypofractionated SRS | 25 Gy in 5 fractions | Large tumors (>8 cc), ONSM | 2a [2][201] |
| Fractionated RT (Photon) | 50.4–59.4 Gy (1.8 Gy/fx) | WHO Grade 2/3, large skull base | 1c [196][28]D |
| Proton Therapy | 54–60 Gy(RBE) | Pediatric cases, complex skull base | 2b [207][77]D |
| SRS for TRTN | 12 Gy (Tumor) + 88 Gy (Nerve) | Tumor-related trigeminal neuralgia | 2b [214] |
Systemic Therapy and Emerging Treatments
- ▸Systemic therapy is only indicated for treatment-refractory meningiomas after surgery and radiotherapy have been exhausted.
- ▸Molecular profiling for NF2, AKT1, SMO, and PIK3CA mutations is mandatory to guide the selection of targeted agents like vismodegib or capivasertib.
- ▸Bevacizumab 10 mg/kg every 2 weeks remains the most evidence-supported first-line systemic option for high-grade or progressive tumors.
Systemic therapy for meningioma is currently reserved for patients with treatment-refractory disease, defined as tumors that progress or recur despite maximal safe surgical resection and optimized radiotherapy [225][232]D. While surgery and radiation remain the primary treatment pillars, approximately 20% of patients present with atypical (WHO grade 2) or malignant (WHO grade 3) variants that exhibit aggressive biological behavior and high recurrence rates [239]D. Historically, cytotoxic chemotherapy has shown negligible efficacy; however, the shift toward precision medicine and molecular profiling has introduced targeted agents and immunotherapies into the clinical landscape [31][232]D.
Step 1: Initial Assessment and Molecular Stratification
The first step in managing refractory meningioma is to define the tumor's molecular landscape to identify actionable targets. According to the 2025 EANO guidelines, molecular testing is now essential for selecting targeted therapies [31]. Clinicians must classify the tumor not only by WHO grade but by its specific mutational profile, as this dictates the choice of systemic agent [31][236]D.
- NF2-mutated: Often associated with increased mTOR signaling; consider mTOR inhibitors or FAK inhibitors [31][233]D.
- SMO/AKT1/PIK3CA-mutated: These non-NF2 mutations are frequently found in skull base meningiomas and are amenable to specific pathway inhibitors [31][220].
- CDKN2A/B loss or CDK4/6 alterations: Predictive of poor prognosis and potential response to cell-cycle inhibitors [31].
- SSTR2A expression: High expression (detected via DOTATATE-PET) identifies candidates for peptide receptor radionuclide therapy (PRRT) [234]D[235].
Step 2: First-Line Systemic Intervention (Anti-angiogenic Therapy)
If local options are exhausted, Bevacizumab 10 mg/kg IV every 2 weeks is the most frequently utilized systemic agent [226]. Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), preventing angiogenesis—a process highly upregulated in aggressive meningiomas [222][226].
In a meta-analysis of 12 studies (n=243), bevacizumab demonstrated a 6-month progression-free survival (PFS-6) of approximately 45-73% for high-grade meningiomas [226]. It is particularly effective in managing peritumoral edema and has shown radiographic responses (≥20% volume reduction) in patients with and co-existing meningiomas [219]. The rationale for its use is based on the high expression of VEGFα in meningioma tissue, which serves as both a biomarker and a therapeutic target [222].
Step 3: Targeted Therapy Selection Based on Driver Mutations
When anti-angiogenic therapy is insufficient or contraindicated, treatment should be tailored to the specific oncogenic drivers identified in Step 1 [31].
- SMO Inhibitors: For tumors harboring SMO mutations, Vismodegib 150 mg PO daily may be considered [31].
- AKT Inhibitors: For AKT1 (E17K) mutations, Capivasertib 400 mg PO twice daily (on a 4-days-on, 3-days-off schedule) is an emerging option [31].
- mTOR Inhibitors: Everolimus 10 mg PO daily has been used, often in combination with octreotide, to target the PI3K/AKT/mTOR pathway, which is frequently activated in NF2-deficient tumors [233]D[235].
- Multi-kinase Inhibitors: Regorafenib 160 mg PO daily (3 weeks on, 1 week off) is currently being evaluated in the MIRAGE trial for grade 2/3 tumors, targeting VEGFR1-3, PDGFR, and FGFR [224].
Step 4: Immunotherapy and Checkpoint Inhibition
For tumors with high PD-L1 expression or those that have failed multiple targeted lines, immune checkpoint inhibitors (ICIs) are an emerging frontier [230]. Meningiomas often harbor an immunosuppressive microenvironment with upregulated PD-L1 on both tumor and infiltrating immune cells [218].
Sintilimab 200 mg IV every 3 weeks was evaluated in a Phase 2 trial (n=40), showing a PFS-6 of 35% for grade 2/3 tumors [218]. While ICIs like pembrolizumab or nivolumab have shown prolonged disease control in small subsets of patients, they are not yet standard of care and should ideally be administered within clinical trials [230][233]D.
Step 5: Radionuclide Therapy and Salvage Protocols
In cases of diffuse or multifocal progression where SSTR2 expression is confirmed by [68Ga]Ga-DOTATATE PET/CT, peptide receptor radionuclide therapy (PRRT) is the preferred salvage strategy [231][234]D.
[177Lu]Lu-DOTATATE (Lutathera) 7.4 GBq (200 mCi) IV every 8 weeks for up to 4 doses is the standard protocol adapted from neuroendocrine tumor [231][235]. The LUMEN-1 trial is currently validating this against standard care, as SSTR2 is nearly universally expressed in meningiomas, allowing for highly targeted delivery of beta-radiation [235]. For patients who fail all systemic lines, the mean survival is approximately 8.94 months, necessitating a transition to palliative care and symptom-focused management [241].
| Drug | Class | Dose/Route | Target | Evidence Level |
|---|---|---|---|---|
| Bevacizumab | Anti-VEGF mAb | 10 mg/kg IV q2w | VEGF-A | 2a [226] |
| Sintilimab | PD-1 Inhibitor | 200 mg IV q3w | PD-1/PD-L1 | 2b [218] |
| Everolimus | mTOR Inhibitor | 10 mg PO daily | mTORC1 | 2b [233]D |
| Vismodegib | SMO Inhibitor | 150 mg PO daily | Hedgehog Pathway | 1c [31] |
| 177Lu-DOTATATE | PRRT | 7.4 GBq IV q8w | SSTR2 | 2b [235] |
| Regorafenib | Multi-TKI | 160 mg PO daily (3/1) | VEGFR, PDGFR, FGFR | 1b [224] |
Prognosis and Recurrence Patterns
- ▸WHO Grade and Simpson grade of resection remain the most powerful traditional predictors of recurrence.
- ▸Molecular markers such as NF2 mutations, CDKN2A/B loss, and DNA methylation profiles provide more accurate risk stratification than morphology alone.
- ▸Radiomic features, including peritumoral edema and normalized ADC values, can preoperatively identify high-grade tumors with aggressive potential.
The prognosis for meningioma is highly variable, dictated primarily by the World Health Organization (WHO) grade, the extent of surgical resection, and emerging molecular signatures. While most meningiomas are benign (WHO Grade 1) and associated with excellent long-term survival, higher-grade lesions (Grade 2 and 3) exhibit aggressive clinical behavior with high rates of recurrence and significant morbidity [69][154]D. Overall, the mortality 3-7% is relatively low for benign cases, and approximately 80% walk independently at 6 months following resection of spinal variants [127].
Survival and Recovery Statistics
Long-term outcomes are generally favorable for WHO Grade 1 tumors, but malignant (Grade 3) meningiomas remain a clinical challenge with poor overall survival and high recurrence rates even after gross total resection (GTR) [69]. In pediatric populations, spinal meningiomas are rare and often associated with distinct histopathology, leading to higher recurrence risks compared to adults [127]. Functional recovery is often robust; for instance, patients undergoing resection for thoracic intradural extramedullary (IDEM) meningiomas show significant improvement on the modified McCormick scale (MMCS), though ventral tumors—which are often larger—may present greater surgical complexity [64].
Recurrence Risk by WHO Grade
Recurrence is the primary concern in meningioma , particularly for atypical and anaplastic variants.
- WHO Grade 1: Low recurrence risk, typically managed with a 'wait-and-scan' approach if incidental and asymptomatic [11].
- WHO Grade 2 (Atypical): Heterogeneous progression patterns. Key risk factors for progression include a high mitotic count (MC) and a Ki-67 index ≥5% [8][124]D.
- WHO Grade 3 (Anaplastic/Malignant): Extremely high recurrence risk. Adjuvant therapies like radiotherapy are standard, though their role in improving long-term survival remains a subject of ongoing investigation [69].
Prognostic Factors
Prognosis is influenced by a combination of surgical, radiological, and molecular factors. The Simpson grade of resection remains a critical predictor; however, in cases of subtotal resection (STR), the surface area of dural attachment and the volume of the remnant (progression defined as a ≥25% increase in volume) are significant predictors of future growth [157]D.
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| WHO Grade | Grade 1 | Grade 2 or 3 [69] |
| Extent of Resection | Simpson Grade I/II (GTR) | Simpson Grade IV/V (STR) [76]D[157]D |
| Molecular Markers | NF2 wild-type | NF2 mutation, CDKN2A/B loss, LOY [45]D[113] |
| Ki-67 Index | < 5% | ≥ 5% [8][124]D |
| Radiology | Homogeneous enhancement | Brain invasion, PTBE, low NADC [142]D[154]D |
Molecular and Radiomic Predictors
Modern risk stratification increasingly relies on molecular profiling and radiomics rather than morphology alone.
- Methylation Classifiers: DNA methylation-based classifiers have been validated to provide superior prognostic stratification compared to traditional WHO grading [243]D.
- Molecular Markers: Loss of the Y chromosome (LOY) in males (found in 9.7% of cases) is significantly associated with higher WHO grades and poorer outcomes [45]D. PD-L1 positivity in MenG C molecular groups identifies a hyper-aggressive subset of tumors [121]D.
- Radiomics: Machine learning models using preoperative MRI can predict tumor consistency, brain invasion, and Ki-67 expression levels with high accuracy [142]D[156]D. For example, a low normalized apparent diffusion coefficient (NADC) and the presence of peritumoral brain edema (PTBE) are independent predictors of high-grade pathology [154]D.
Long-Term Sequelae and Recurrence Management
Survivors may face long-term challenges including seizures, visual deficits, and psychological impact. In pediatric cohorts, seizures are a frequent presenting symptom, though surgical resection often leads to improved seizure control [11]. For recurrent or progressive tumors where surgery and radiation are exhausted, systemic options are limited. Trials have investigated abemaciclib (a CDK 4/6 inhibitor) for tumors with CDK pathway alterations, using a 6-month progression-free survival (PFS6) endpoint [113]. Similarly, the PD-1 inhibitor sintilimab 200 mg every 3 weeks has been evaluated in recurrent cases [218].
Natural History and Follow-up Protocol
For patients with incidental or subtotally resected tumors, a structured follow-up is essential to detect early progression.
- Step 1: Baseline postoperative MRI within 48 hours to assess the extent of resection and remnant volume [157]D.
- Step 2: Serial imaging every 6-12 months for Grade 1 tumors, or more frequently (3-6 months) for Grade 2/3 lesions [8].
- Step 3: Utilization of radiomic features and molecular markers (e.g., FOXC1 expression) to identify patients at high risk for peritumoral edema or rapid recurrence [141]D.
| Category | Factor | Clinical Significance |
|---|---|---|
| Histopathology | Mitotic Count (MC) | Higher count correlates with Grade 2/3 and rapid progression [8] |
| Immunohistochemistry | Ki-67 Index | Threshold of ≥5% indicates high proliferation and recurrence risk [124]D |
| Molecular | Loss of Y (LOY) | Associated with higher grade and worse prognosis in males [45]D |
| Radiology | Brain Invasion | Independent diagnostic criterion for WHO Grade 2; predicts recurrence [142]D |
| Radiology | PTBE | Peritumoral brain edema correlates with FOXC1 expression and higher grade [141]D[154]D |
Special Populations: Pediatric and Genetic Syndromes
- ▸Pediatric meningiomas are rare (1-5% of cases) and frequently harbor unique molecular drivers like YAP1-MAML2 fusions rather than standard adult mutations.
- ▸NF2-related schwannomatosis requires a multidisciplinary approach to manage a high multi-tumor burden, utilizing a combination of surveillance, radiosurgery, and emerging systemic agents like CDK4/6 inhibitors.
- ▸Molecular markers such as SMARCE1, BAP1, and loss of the Y chromosome are critical for identifying aggressive phenotypes in special populations.
Meningiomas in special populations, particularly children and those with genetic predispositions, represent a distinct clinical entity compared to the more common sporadic adult cases. While adult meningiomas are often slow-growing and solitary, pediatric and syndromic variants frequently exhibit aggressive behavior, unique molecular drivers, and a high cumulative tumor burden [245][250]D.
Pediatric Meningiomas
Pediatric meningiomas (PMs) are rare, accounting for only 1% to 5% of all primary central nervous system tumors in children [245][77]D. Unlike the female predominance seen in adults, PMs show a more balanced male-to-female ratio, often cited as 1:1 [77]D.
Diagnostic and Molecular Considerations PMs are molecularly distinct from adult variants. While NF2 mutations remain common, children frequently harbor unique alterations such as YAP1-MAML2 fusions [247]C. These fusions are associated with activated YAP1 signaling and often present as atypical intraparenchymal lesions that may mimic vascular malformations or gliomas on imaging [247]C. Additionally, PMs are more likely to present as hyperostotic variants, characterized by significant bony invasion and infiltration of dural sinuses, which complicates surgical resection [249]C.
and Prognosis The primary treatment for PMs is maximal safe surgical resection. However, the extent of resection (EOR) is a critical determinant of progression-free survival (PFS) [245]. When gross total resection is not feasible or in cases of WHO grade 2 disease, adjuvant therapy is required.
- Proton Therapy (PT): PT is preferred in children to minimize late toxicities. Standard dosing ranges from 50.4 to 59.4 Gy delivered in 1.8 Gy fractions [77]D.
- Prognosis: Pediatric patients generally have a higher rate of high-grade (WHO grade 2 or 3) tumors compared to adults [245]. Longitudinal data suggests that while 3-year survival is high, the risk of recurrence remains significant, particularly in patients with underlying genetic syndromes [245][77]D.
(NF2-SWN)
Neurofibromatosis type 2 (now termed NF2-related schwannomatosis) is the most significant genetic predisposition for meningioma. These patients often develop multiple, synchronous meningiomas throughout the neuraxis [203][250]D.
Clinical Presentation and Challenges NF2-associated meningiomas typically appear at a younger age and exhibit a higher growth rate than sporadic cases [250]D. The management is exceptionally complex due to the "multi-tumor burden," where clinicians must balance the risk of tumor progression against the cumulative morbidity of multiple surgeries or radiation treatments [203][250]D. Spinal meningiomas are also prevalent in this population, often requiring surgical intervention when they become symptomatic or cause cord compression [253]D.
Management Protocol for NF2-Associated Meningiomas
- Step 1: Surveillance. Annual or semi-annual MRI of the brain and spine to monitor tumor kinetics. Intervention is deferred for asymptomatic, stable lesions [250]D.
- Step 2: Targeted Intervention. If a specific lesion shows rapid growth or causes focal deficits, localized treatment is prioritized.
- Gamma Knife Radiosurgery (GKRS): Effective for small-to-medium tumors. Meta-analyses show a 100% 3-year survival rate, though long-term tumor control in NF2 may be lower than in sporadic cases [203][205].
- Surgery: Reserved for large, symptomatic, or rapidly progressing lesions where radiation is contraindicated or unlikely to succeed [250]D.
- Step 3: Systemic Pharmacotherapy. For patients with progressive disease not amenable to local therapy, systemic options are considered:
- Bevacizumab: May be used for progressive vestibular schwannomas; however, its effect on co-existing meningiomas is modest, with only approximately 2.5% of meningiomas showing a radiographic response (defined as ≥20% volume reduction) [219].
- Abemaciclib: A CDK4/6 inhibitor (dose: 200 mg twice daily) has shown promise in meningiomas with NF2 or CDK pathway alterations, achieving a 6-month PFS (PFS6) of 54% in grade 2/3 tumors [113].
- Experimental Combinations: Preclinical data suggest that combining Brigatinib (a multikinase inhibitor) with mTOR inhibitors (e.g., INK128) may potently inhibit NF2-deficient tumor growth [252]D.
Other Genetic Predispositions and Rare Entities
Beyond NF2, several other germline and somatic mutations define specific meningioma populations:
- SMARCE1 and BAP1: Germline mutations in SMARCE1 are associated with clear cell meningiomas, often in pediatric patients, while BAP1 mutations are linked to highly aggressive rhabdoid variants [31].
- Meningioangiomatosis (MA): A rare, benign condition that can be sporadic or associated with NF2. It involves meningothelial and vascular proliferation within the cerebral cortex, often presenting with refractory seizures [43]D.
- Male-Specific Factors: While less common in men, male meningiomas are more frequently high-grade. This is increasingly linked to the loss of the Y chromosome (LOY), which is found in approximately 9.7% of male cases and correlates with higher WHO grades [45]D.
- Minute Pulmonary Meningothelial-like Nodules (MPMNs): These are benign lung lesions histologically similar to meningiomas. They are often incidental findings and must be distinguished from metastatic meningioma [53]D.
| Feature | Pediatric Meningioma | Adult Meningioma |
|---|---|---|
| Incidence | 1-5% of all meningiomas [245] | Most common primary CNS tumor [31] |
| Sex Distribution | Approximately 1:1 [77]D | Strong female predominance (approx. 3:1) [33]D |
| Common Drivers | NF2, YAP1 fusions, SMARCE1 [247]C[31] | NF2, TRAF7, AKT1, KLF4 [31] |
| WHO Grade | Higher frequency of Grade 2/3 [245] | Predominantly Grade 1 [248]D |
| Location | Often convexity or intraventricular [249]C | Variable (skull base, convexity, parasagittal) [255]D |
| Bone Involvement | Frequent hyperostosis/invasion [249]C | Less common in benign variants |
| Agent | Mechanism | Clinical Context | Evidence |
|---|---|---|---|
| Abemaciclib | CDK4/6 Inhibitor | Recurrent/Progressive Grade 2/3 with NF2 or CDK alterations | Phase 2 (PFS6: 54%) [113] |
| Bevacizumab | VEGF Inhibitor | Primarily for vestibular schwannoma; limited effect on meningioma | Retrospective (2.5% RR) [219] |
| Brigatinib + mTORi | Multikinase + mTOR Inhibition | Experimental for NF2-deficient tumors | Preclinical/In vitro [252]D |
| Targeted Agents | SMO, AKT1, PIK3CA inhibitors | Based on specific molecular profiling | Guideline-recommended [31] |
Guidelines and Resources
- ▸Molecular biomarkers like CDKN2A/B and BAP1 are now essential for accurate grading and predicting aggressive behavior beyond traditional histology [31, 274].
- ▸(68)Ga-DOTATATE PET/CT is a superior diagnostic tool for delineating tumor margins in complex locations compared to MRI alone [257, 271].
- ▸Stereotactic radiosurgery (SRS) is a primary or adjuvant treatment option for benign meningiomas with high 10-year local control rates [260].
The of meningioma has evolved from a purely histopathological approach to a multidisciplinary paradigm integrating advanced molecular diagnostics and functional imaging. Current guidelines emphasize the importance of personalized treatment based on tumor grade, molecular markers, and patient-specific factors such as age and comorbidities [259][274]D.
Diagnostic and Molecular Guidelines
While (MRI) remains the gold standard for provisional diagnosis, the European Association of Neuro-Oncology (EANO) and the International Consortium on Meningiomas now advocate for the integration of molecular biomarkers into the grading and prognostication process [259][274]D. The 2025 EANO guidelines specifically recommend molecular testing for tumors that progress or recur to identify targets for systemic therapy [31].
Key molecular markers include NF2, AKT1, SMO, and CDKN2A/B [31]. Loss of BAP1 or CDKN2A/B homozygous deletion is associated with aggressive behavior regardless of histological grade [31]. Furthermore, the use of (68)Ga-DOTATATE PET/CT is increasingly recognized as a critical tool for delineating tumor extent, especially in complex skull base lesions where MRI may be ambiguous [271]D[257]. This is because somatostatin receptor 2 (SSTR2) is almost universally expressed in meningioma tissue [202].
Management and Surgical Guidelines
Surgery remains the primary treatment for symptomatic or growing meningiomas [196][261]. The Association of French-speaking Neuro-oncologists (ANOCEF) and the French Society for Radiation Oncology (SFRO) emphasize that indications for intervention must be discussed in multidisciplinary panels [258][196]. For asymptomatic, incidental, or elderly patients, a "wait-and-scan" approach is often preferred [259].
In low- and middle-income countries (LMICs), guidelines suggest prioritizing surgical resection for lesions causing significant mass effect, while acknowledging that access to advanced facilities like intraoperative MRI or specialized radiosurgery may be limited [263]. For intraventricular meningiomas, there is no universal consensus on the optimal surgical approach, though the transtemporal and transparietal routes are most common [273]D.
Radiotherapy and Radiosurgery Guidelines
Radiotherapy (RT) is indicated as an adjuvant treatment for WHO Grade 3 tumors, and increasingly for WHO Grade 2 tumors with subtotal resection [259][269]C. The International Stereotactic Radiosurgery Society (ISRS) provides strong evidence for the use of (SRS) in benign (WHO Grade 1) meningiomas, reporting 10-year local control rates between 71% and 100% [260].
Protocol: SSTR-PET Guided Radiation Planning
Step 1 → Perform (68)Ga-DOTATATE PET/CT to identify residual or additional disease not visible on MRI [202]. Step 2 → Co-register PET/CT with high-resolution MRI for target volume delineation [257]. Step 3 → Define the Gross Tumor Volume (GTV) by combining PET-positive regions with MRI-enhancing areas to minimize toxicity and maximize local control [202][271]D.
Surveillance and Long-term Follow-up
Post-treatment surveillance is essential due to the risk of late recurrence, even in benign lesions. EANO guidelines suggest annual MRI for the first 5 years, followed by biennial scans if the tumor remains stable [259]. For higher-grade tumors (WHO Grade 2 and 3), more frequent imaging (every 3–6 months) is required [259]. Clinicians must also monitor for neurocognitive impairment, which is a frequently underreported but significant impact of both the tumor and its treatment [265].
| Organization | Year | Key Recommendations |
|---|---|---|
| EANO [259][31] | 2021/2025 | Integration of molecular markers (NF2, CDKN2A/B); observation for asymptomatic Grade 1. |
| ISRS [260] | 2020 | SRS is established for benign meningiomas; 10-year local control 71-100%. |
| ANOCEF/SFRO [258][196] | 2023/2025 | Multidisciplinary panel review; standardized target volume delineation for RT. |
| EANM/EANO/RANO [257] | 2024 | Practice standards for SSTR-ligand PET/CT in diagnostics and theranostics. |
| LMIC Consensus [263] | 2024 | Tailored management strategies for resource-limited settings; focus on mass effect. |
References
- [1]
Ateiwi YA, Mahmood R, Wong HJ et al.. “Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 41722869 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [2]
Pahwa B, Pahwa N, Sheehan JP. “Single session versus hypofractionated stereotactic radiosurgery for large meningiomas (> 8 cc): a systematic review and meta analysis.” Journal of neuro-oncology (2025). PMID: 41291309 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Surgical Management and Techniques, Radiation Therapy and Radiosurgery - [3]
Sun Z. “Comparative Efficacy of Remimazolam Versus Propofol in Meningioma Surgery with Scalp Nerve Block.” Medical science monitor : international medical journal of experimental and clinical research (2025). PMID: 41076554 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Prognosis and Recurrence Patterns - [4]
Singh R, Koempel A, French B et al.. “Improved progression-free survival following dose-escalated vs. standard dose post-operative radiation therapy for high-risk meningiomas: An International Multicenter Individual Patient Level Meta-Analysis (FIRESTORM).” International journal of radiation oncology, biology, physics (2026). PMID: 41956162 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [5]
Krzemińska A, Więcław J, Koźba-Gosztyła M et al.. “Radiation-Induced Meningiomas: Systematic Review with Pooled Case Analysis and Case Series of Long Latency, Aggressive Behavior, and Clinical Outcomes.” Journal of clinical medicine (2026). PMID: 41899280 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [6]
Falcao V, Rego LHRM, Rodrigues PB et al.. “Hormone therapy and the risk of central nervous system tumors in women: a systematic review and meta-analysis.” Journal of neuro-oncology (2026). PMID: 41721900 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [7]
Alare K, Afolabi SA, Adetunji B et al.. “Trends of hospital-based reporting of intracranial neoplasms in Nigeria from 1960 to 2024: A systematic review and pooled analysis of literatures.” Neuro-oncology advances (2025). PMID: 41323960 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [8]
Byun YH, Han M, Nam SM et al.. “Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.” Acta neurochirurgica (2025). PMID: 41324743 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Classification and WHO Grading, Immunohistochemistry and Molecular Markers, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [9]
Mahjari A, Alyazidi A, El-Sayed K et al.. “Traumatic Brain Injury and Risk of Intracranial Meningioma : A Systematic Review and Meta-Analysis.” Journal of Korean Neurosurgical Society (2026). PMID: 41921582 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [10]
Tettamanti G, Shu X, Mogensen H et al.. “Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study.” Neuro-oncology (2026). PMID: 41056434 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Prognosis and Recurrence Patterns - [11]
Ye E, Hines D, Reddy SB et al.. “Pediatric meningioma and seizures: a single-center cohort study.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2026). PMID: 41526775 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns, Guidelines and Resources - [12]
Fadhil Hashim A, Karimi A, Ghanbari S et al.. “Ambient Air Pollution and Risk of Brain Tumors: A Systematic Review and Meta-Analysis.” Asian Pacific journal of cancer prevention : APJCP (2026). PMID: 41660899 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [13]
Smerdi D, Anastasopoulos L, Charalampopoulou E et al.. “Coexistence of histologically distinct intracranial tumors: Case series, literature review, and meta-analysis.” Surgical neurology international (2026). PMID: 41952732 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [14]
Almeida ND, Sinha S, Fang M et al.. “Radiation-induced meningiomas: A systematic review and meta-analysis of 927 meningiomas.” Surgical neurology international (2026). PMID: 41660311 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [15]
Passeri T, Alcântara T, Fava A et al.. “Chopsticks mononostril approach with sphenoid sinus cranialization and septal mucosa suturing: a new minimally invasive concept and closure technique for endoscopic endonasal approaches.” Journal of neurosurgery (2026). PMID: 41825064 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [16]
Zeng W, Jedwood C, Chung R et al.. “Associations of surgical menopause and hormone replacement therapy with meningioma development.” Journal of neuro-oncology (2026). PMID: 41817782 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [17]
Edwards E, Tsai K, Pappu S et al.. “Incidence of meningioma in women with a history of combined oral contraceptive pill use and polycystic ovary syndrome.” Women's health (London, England) (2026). PMID: 41699937 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [18]
Ko SW, Won YD, Ha BJ et al.. “Optimal α/β Ratio for Biologically Effective Dose-Based Prediction of Radiation-Induced Peritumoral Brain Edema in Meningioma.” Cancers (2026). PMID: 41681920 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [19]
Leistner T, Terrapon APR, Hostettler IC et al.. “Adverse events in meningioma surgery classified using the therapy-disability-neurology (TDN) grading system.” Journal of neuro-oncology (2025). PMID: 41400878 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Surgical Management and Techniques - [20]
Naert L, Stroobants S, Vandamme T et al.. “The prevalence and clinical significance of 68Ga-DOTANOC incidentaloma.” Endocrine-related cancer (2026). PMID: 41395644 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [21]
Bowers DC, Cooney T, Chen Y et al.. “Subsequent Meningiomas Among Survivors of Childhood Cancer.” JAMA network open (2025). PMID: 41379444 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [22]
Holmgren K, Fletcher-Sandersjöö A, Sæmundsson B et al.. “Cranioplasty after surgical site infection in brain tumor patients: insights from a 15-year Swedish multicenter study.” Journal of neurosurgery (2026). PMID: 41349038 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [23]
Jiang C, McWilliams T, Berger M et al.. “Periventricular radionecrosis after conventionally fractionated radiation for low grade meningiomas.” Radiation oncology (London, England) (2025). PMID: 41291917 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [24]
Islim AI, Millward CP, Zakaria R et al.. “A Clinical Tool to Identify Incidental Meningioma for Early Outpatient Management.” JAMA oncology (2026). PMID: 41264316 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnostic Imaging and Radiology, Special Populations: Pediatric and Genetic Syndromes - [25]
Albarracín Cárdenas CI, Caballero Rojas H, Ochoa Vera ME et al.. “Survival of nervous system tumors in a Colombian population cancer registry.” Journal of neuro-oncology (2025). PMID: 41247425 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [26]
Lenga P, Scherer M, Dao Trong P et al.. “Sex-specific disparities in postoperative adverse events following intracranial tumor surgery: insights from a tertiary neurosurgical center.” Acta neurochirurgica (2025). PMID: 41231356 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [27]
Khalili BF, Chojnacki MR, Dixit K et al.. “Surgical Treatment of Brain Tumor-Related Epilepsy: Current and Emerging Strategies.” Cancers (2025). PMID: 41228332 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [28]
Tas KT, Höft FS, Agolli L et al.. “Long-term outcomes and toxicity of radiotherapy for WHO Grade II and III meningiomas: a retrospective analysis of 98 patients.” Journal of neuro-oncology (2025). PMID: 41134468 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Classification and WHO Grading, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Radiation Therapy and Radiosurgery - [29]
Rai P, Mehta T, Kumar SS et al.. “Metastatic Meningioma: Neuroradiologic and Molecular Imaging Perspectives.” Radiology. Imaging cancer (2025). PMID: 41104976 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Immunohistochemistry and Molecular Markers, Diagnostic Imaging and Radiology, Systemic Therapy and Emerging Treatments - [30]
Price M, Ballard CAP, Benedetti JR et al.. “CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022.” Neuro-oncology (2025). PMID: 41092086 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [31]
Sahm F, Bertero L, Brandner S et al.. “European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.” Neuro-oncology (2025). PMID: 39577862 ↗
L1cGUIDELINECited in: Etiology and Molecular Pathogenesis, Systemic Therapy and Emerging Treatments, Special Populations: Pediatric and Genetic Syndromes, Guidelines and Resources - [32]
Chen A, Hart SL, Lannon M et al.. “Meningiomas in Rubinstein-Taybi syndrome: A case report and comprehensive review.” Journal of neuropathology and experimental neurology (2025). PMID: 39740655 ↗
L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis - [33]
Huo X, Wang L, Ma J et al.. “Bibliometric analysis of publication trends in meningioma research (1992 - 2023).” Neurosurgical review (2025). PMID: 40779080 ↗
L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis, Immunohistochemistry and Molecular Markers, Systemic Therapy and Emerging Treatments, Special Populations: Pediatric and Genetic Syndromes - [34]
Lotsch C, Warta R, Herold-Mende C. “The Molecular and Immunological Landscape of Meningiomas.” International journal of molecular sciences (2024). PMID: 39273576 ↗
L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis, Systemic Therapy and Emerging Treatments - [35]
Hsieh AL, Bi WL, Ramesh V et al.. “Evolving concepts in meningioma management in the era of genomics.” Cancer (2024). PMID: 38753473 ↗
L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis, Special Populations: Pediatric and Genetic Syndromes - [36]
Caccese M, Busato F, Guerriero A et al.. “The role of radiation therapy and systemic treatments in meningioma: The present and the future.” Cancer medicine (2023). PMID: 37366279 ↗
L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis - [37]
Cumpston EC, Rhodes SD, Yates CW. “Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.” Current oncology reports (2023). PMID: 36933171 ↗
L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis - [38]
Wu JP, Yu L, Mu CP et al.. “A Rare Instance of Rosai-dorfman Disease With Mimicking Meningioma.” The Journal of craniofacial surgery (2025). PMID: 39902913 ↗
L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis, Gross and Microscopic Features, Immunohistochemistry and Molecular Markers - [39]
Cheng J, Guo C. “Primary pulmonary meningioma: a case report and literature review.” Journal of cardiothoracic surgery (2025). PMID: 39773541 ↗
L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis, Systemic Therapy and Emerging Treatments - [40]
Shimasaki T, Akutsu N, Koyama J et al.. “Pediatric intraparenchymal meningioma in the basal ganglia treated with gross total resection: a case report and review of the literature.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2023). PMID: 37369950 ↗
L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis - [41]
Trabzonlu L, Martinez-Lage M, Deschler D et al.. “FNA of Meningioma with Rhabdoid Features Presenting as a Lateral Neck Mass.” Head and neck pathology (2024). PMID: 38658429 ↗
L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis - [42]
Sadagopan NS, Nandoliya KR, Youngblood MW et al.. “A novel BRAF::PTPRN2 fusion in meningioma: a case report.” Acta neuropathologica communications (2023). PMID: 38066633 ↗
L4CASE_REPORTCited in: Etiology and Molecular Pathogenesis - [43]
Mansour MA, Mostafa HN, Elsamman AK. “Decoding Meningioangiomatosis: A Century of Insights into Molecular Mechanisms, Clinical Dilemmas, and Therapeutic Innovations.” World neurosurgery (2026). PMID: 41325933 ↗
L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis, Surgical Management and Techniques, Special Populations: Pediatric and Genetic Syndromes - [44]
Graillon T, Tabouret E, Salgues B et al.. “Innovative treatments for meningiomas.” Revue neurologique (2023). PMID: 36959063 ↗
L5REVIEW_NARRATIVECited in: Etiology and Molecular Pathogenesis - [45]
Sakaguchi M, Horie M, Ito Y et al.. “Clinicopathological significance of loss of Y chromosome in male meningiomas.” The Journal of pathology (2026). PMID: 41715910 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis, Classification and WHO Grading, Prognosis and Recurrence Patterns, Special Populations: Pediatric and Genetic Syndromes - [46]
Zhang L, Ye Y, Gu W et al.. “KMT2C Loss Promotes NF2-Wildtype Meningioma Progression and Ferroptosis Sensitivity via Epigenetic Repression of Hippo Signaling.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41642951 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis, Special Populations: Pediatric and Genetic Syndromes - [47]
Ohara K, Miyawaki S, Teranishi Y et al.. “Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas.” Acta neuropathologica communications (2025). PMID: 41250239 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis, Immunohistochemistry and Molecular Markers - [48]
Drabent P, Touat M, Benusiglio PR et al.. “A Specific Methylation Class Identifies BAP1-Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid Histology.” Neuropathology and applied neurobiology (2025). PMID: 41024725 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis - [49]
Alkhatib M, Hua L, Beyer F et al.. “Molecular landscape and clinical correlates of olfactory groove meningiomas: a multi-institutional study.” Journal of neurosurgery (2025). PMID: 40911921 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis, Classification and WHO Grading - [50]
Kashiwagi-Hakozaki M, Ikemura M, Miyawaki S et al.. “Merlin immunohistochemistry is a reliable surrogate marker for NF2 gene alterations in meningioma.” Histopathology (2025). PMID: 40815185 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis, Classification and WHO Grading, Gross and Microscopic Features, Special Populations: Pediatric and Genetic Syndromes - [51]
Shah M, Akther Y, Adams CL et al.. “Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomas.” EBioMedicine (2025). PMID: 40562609 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis, Special Populations: Pediatric and Genetic Syndromes - [52]
Tollefsen SE, Meta R, Solheim O et al.. “Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas.” Journal of neuropathology and experimental neurology (2025). PMID: 40447281 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis, Gross and Microscopic Features, Special Populations: Pediatric and Genetic Syndromes - [53]
Li H, Huang Z, Wang Y et al.. “Clinicopathologic and Genomic Characteristics of Minute Pulmonary Meningothelial-like Nodules.” Laboratory investigation; a journal of technical methods and pathology (2025). PMID: 40311876 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis, Special Populations: Pediatric and Genetic Syndromes - [54]
Sievers P, Arora S, Hielscher T et al.. “Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes.” Neuro-oncology (2025). PMID: 40249111 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis - [55]
Dedhia M, Devarajan A, Rao A et al.. “Somatic AKT1 Mutations May Confer Increased Risk of Preoperative Seizures in Meningiomas.” Neurosurgery (2025). PMID: 40214250 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis - [56]
Tang H, Xu F, Sun D et al.. “Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.” CNS neuroscience & therapeutics (2025). PMID: 39996452 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis - [57]
Mair MJ, Hartenbach S, Tomasich E et al.. “Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.” European journal of nuclear medicine and molecular imaging (2025). PMID: 39969538 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis - [58]
Zhang N, Shen X, Yu Y et al.. “Lead exposure promotes NF2-wildtype meningioma cell proliferation through the Merlin-Hippo signaling pathway.” Environmental health and preventive medicine (2025). PMID: 39894505 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis - [59]
Ren L, Deng J, Wakimoto H et al.. “Clinical and molecular characteristics and long-term outcomes of pediatric intracranial meningiomas: a comprehensive analysis from a single neurosurgical center.” Acta neuropathologica communications (2025). PMID: 39856730 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis - [60]
Devarajan A, Seah C, Zhang JY et al.. “A four-hit mechanism is sufficient for meningioma development.” Journal of neuro-oncology (2025). PMID: 39586894 ↗
L5OTHERCited in: Etiology and Molecular Pathogenesis - [61]
Cordia QCF, Dijkstra BM, Groen RJM. “The dural tail in intracranial meningioma: Heads up or tail down? A systematic review of the literature.” Neurosurgical review (2025). PMID: 40542302 ↗
L2aSR_OBSCited in: Classification and WHO Grading - [62]
Dono A, Pichardo-Rojas D, Mendoza Mora L et al.. “MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review.” Journal of neuropathology and experimental neurology (2025). PMID: 40249413 ↗
L2aSR_OBSCited in: Classification and WHO Grading, Gross and Microscopic Features, Immunohistochemistry and Molecular Markers - [63]
Khaleghi M, Tao M, Dyess G et al.. “Comparative analysis of facial nerve outcomes in petroclival versus posterior petrous meningioma surgery: A systematic review and meta-analysis of 2884 patients.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40578007 ↗
L2aSR_OBSCited in: Classification and WHO Grading - [64]
Suematsu Y, Nagoshi N, Okubo T et al.. “Comparison of surgical and clinical outcomes between ventral and dorsal/lateral thoracic intradural extramedullary meningiomas: a retrospective study.” Spinal cord (2026). PMID: 41145830 ↗
L2bCOHORTCited in: Classification and WHO Grading, Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns - [65]
Gaggero G, Pesaresi A, Giunti D et al.. “PD-L1 expression pattern as predictive factor of biological behaviour in intracranial meningiomas: A single-center retrospective study.” European journal of clinical investigation (2026). PMID: 40990537 ↗
L2bCOHORTCited in: Classification and WHO Grading, Gross and Microscopic Features, Immunohistochemistry and Molecular Markers - [66]
Lee CC, Wujanto C, Handa P et al.. “The value of radiotherapy in patients with recurrent atypical meningioma: an update.” Expert review of neurotherapeutics (2025). PMID: 40944339 ↗
L5REVIEW_NARRATIVECited in: Classification and WHO Grading - [67]
He T, Zhang Z, Wang X. “A huge cerebral parenchymal meningioma in sylvian fissure: case report and literature review.” BMC neurology (2025). PMID: 40188049 ↗
L4CASE_REPORTCited in: Classification and WHO Grading, Clinical Presentation and Neurological Manifestations - [68]
Eghtedari M, Mitchell WG, Hardy TG. “Atypical Optic Nerve Sheath Meningioma With Postbiopsy Ophthalmic Artery Occlusion.” Ophthalmic plastic and reconstructive surgery (Unknown). PMID: 40153799 ↗
L4CASE_REPORTCited in: Classification and WHO Grading, Gross and Microscopic Features - [69]
Aman RA, Amelia R, Arqursoy H et al.. “Insights on Survival and Recurrence After Surgery in Malignant Meningiomas: A Systematic Review and Meta-Analysis.” Asian Pacific journal of cancer prevention : APJCP (2025). PMID: 41312917 ↗
L2aSR_OBSCited in: Classification and WHO Grading, Immunohistochemistry and Molecular Markers, Surgical Management and Techniques, Radiation Therapy and Radiosurgery, Systemic Therapy and Emerging Treatments, Prognosis and Recurrence Patterns - [70]
Caldonazzi N, Hernandez Gamero G, Mafficini A et al.. “Relevance of next-generation sequencing in the differential diagnosis of meningeal mesenchymal tumors: primary meningeal dedifferentiated chondrosarcoma of the cavernous sinus.” Pathologica (2025). PMID: 41954345 ↗
L4CASE_REPORTCited in: Classification and WHO Grading - [71]
D'Andrea M, Costanzo R, Fuschillo D et al.. “Comparative outcomes of giant versus non-giant anterior clinoidal meningiomas: A single-center case series with extended follow-up.” Neurosurgical review (2025). PMID: 41326908 ↗
L4CASE_REPORTCited in: Classification and WHO Grading, Clinical Presentation and Neurological Manifestations, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [72]
Shao X, Xu Z, Liu P et al.. “TERT promoter C250T mutation in a recurrent cervical chordoid meningioma: a unique case report.” World journal of surgical oncology (2025). PMID: 41013491 ↗
L4CASE_REPORTCited in: Classification and WHO Grading, Immunohistochemistry and Molecular Markers - [73]
Fujiwara K, Shibao S, Sasao R et al.. “Endoscopic-assisted contralateral interhemispheric transfalcine keyhole approach for falcine meningioma: How I do it.” Acta neurochirurgica (2025). PMID: 40126699 ↗
L4CASE_REPORTCited in: Classification and WHO Grading - [74]
Ye E, Gupta A, Lyons AT et al.. “Pediatric meningioma and seizures: A scoping review.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2025). PMID: 40637916 ↗
L5REVIEW_NARRATIVECited in: Classification and WHO Grading, Clinical Presentation and Neurological Manifestations - [75]
Deng D, Yang Y, Cheng B et al.. “Middle ear lymphoepithelioma-like carcinoma with cerebellopontine angle invasion misdiagnosed as meningioma: A case report and literature review.” The Journal of international medical research (2026). PMID: 41986889 ↗
L4CASE_REPORTCited in: Classification and WHO Grading, Surgical Management and Techniques - [76]
Fukami S, Akimoto J, Nagai K et al.. “Photodynamic therapy using talaporfin sodium for grade 2/3 meningiomas: a preliminary study of safety, feasibility, and clinical outcomes.” Journal of neuro-oncology (2026). PMID: 41917547 ↗
L5OTHERCited in: Classification and WHO Grading, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [77]
Thompson E, Indelicato DJ, Brisson RJ et al.. “Outcomes Following Proton Radiation for Pediatric Meningiomas.” Pediatric blood & cancer (2026). PMID: 41496666 ↗
L5OTHERCited in: Classification and WHO Grading, Radiation Therapy and Radiosurgery, Prognosis and Recurrence Patterns, Special Populations: Pediatric and Genetic Syndromes - [78]
Wang M, Ding M, Xia W et al.. “Microsurgical resection of skull base meningioma involving internal carotid artery: The power of blood flow reconstruction.” Neurosurgical review (2025). PMID: 41369922 ↗
L5OTHERCited in: Classification and WHO Grading, Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [79]
Jhandi S, Goold E, Jensen RL. “Meningioma grade and molecular markers of proliferation, hypoxia, and vascularity as predictors of outcome in a cohort with long-term patient follow-up.” Journal of neuro-oncology (2025). PMID: 41094320 ↗
L5OTHERCited in: Classification and WHO Grading - [80]
Luo XX, Peng B, Wang JH et al.. “Identification of a Novel Oxidative Stress-Based Molecular Classification and Treatment Vulnerabilities in WHO Grade 2/3 Meningiomas.” Oncology research (2025). PMID: 41050085 ↗
L5OTHERCited in: Classification and WHO Grading, Guidelines and Resources - [81]
Diebold M, Becker L, Demerath T et al.. “Non-invasive Prediction of Meningioma Tumor Grade by Quantification of Shape-based Radiomics Features and Surface Regularity.” Clinical neuroradiology (2026). PMID: 40960507 ↗
L5OTHERCited in: Classification and WHO Grading - [82]
Haddad AF, Ramesh R, Zakimi N et al.. “Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.” Neuro-oncology (2025). PMID: 40916651 ↗
L5OTHERCited in: Classification and WHO Grading - [83]
Wei CZ, Niranjan A, Deng H et al.. “The 35-Year Evolution of Stereotactic Radiosurgery for Meningiomas.” Neurosurgery (2026). PMID: 40844288 ↗
L5OTHERCited in: Classification and WHO Grading, Radiation Therapy and Radiosurgery - [84]
Saadh MJ, Albadr RJ, Sur D et al.. “Reproducible meningioma grading across multi-center MRI protocols via hybrid radiomic and deep learning features.” Neuroradiology (2025). PMID: 40824403 ↗
L5OTHERCited in: Classification and WHO Grading - [85]
Peng TC, Hsieh MH, Lin CF et al.. “Repeated stereotactic radiosurgery for high grade meningioma.” Journal of neuro-oncology (2025). PMID: 40802120 ↗
L5OTHERCited in: Classification and WHO Grading, Radiation Therapy and Radiosurgery - [86]
Gomes FC, Ferreira MY, Pereira MAOM et al.. “Fully endoscopic approach to cerebellopontine angle tumors: a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 41251909 ↗
L2aSR_OBSCited in: Gross and Microscopic Features, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [87]
Ferreira MY, Scarramal JPL, Cheidde L et al.. “Treatment and outcomes of concomitant parasellar meningiomas and anterior circulation aneurysms: a systematic review and perspective in the endovascular era.” Neurosurgical review (2025). PMID: 40338346 ↗
L2aSR_OBSCited in: Gross and Microscopic Features, Clinical Presentation and Neurological Manifestations - [88]
Huang W, Liao J, Liu T et al.. “Unilateral biportal endoscopy for the treatment of high-grade thoracic spinal meningioma: a case report and review of the literature.” Journal of cancer research and clinical oncology (2025). PMID: 41071365 ↗
L4CASE_REPORTCited in: Gross and Microscopic Features - [89]
Di Lorenzo S, Farese S, Balbo C et al.. “The First Case Report of a Solitary Pulmonary Metastasis of a Transitional Meningioma and Literature Review.” International journal of molecular sciences (2025). PMID: 40725113 ↗
L4CASE_REPORTCited in: Gross and Microscopic Features - [90]
Jung A, Brodhun M, Lemmer A et al.. “Meningioma and Cerebral Spindle Cell Sarcoma as Two Different Metachronous Tumor Entities Secondary to Medulloblastoma Treatment in Childhood: Case Report and Review of the Literature.” Journal of neurological surgery. Part A, Central European neurosurgery (2026). PMID: 40404129 ↗
L4CASE_REPORTCited in: Gross and Microscopic Features - [91]
Tomakin F, Engin R, Şener H et al.. “Impact of BrainLab VectorVision Infrared-Based Neuronavigation on Surgical Outcomes in Intracranial Meningioma Patients: A Retrospective Study.” Medical science monitor : international medical journal of experimental and clinical research (2024). PMID: 38990791 ↗
L2bCOHORTCited in: Gross and Microscopic Features - [92]
Li Y, Li Y, Liu J et al.. “Concurrent spinal meningioma and giant invasive schwannoma without neurofibromatosis in children: A case report and literature review.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2024). PMID: 38349526 ↗
L4CASE_REPORTCited in: Gross and Microscopic Features - [93]
Aung TM, Ngamjarus C, Proungvitaya T et al.. “Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.” PloS one (2024). PMID: 38758750 ↗
L2aSR_OBSCited in: Gross and Microscopic Features - [94]
Shi Z, Yang B, Shen C. “Important role of endoscope in tuberculum sellae meningioma resection via supraorbital keyhole approach.” Acta neurochirurgica (2025). PMID: 40047981 ↗
L4CASE_REPORTCited in: Gross and Microscopic Features - [95]
Peters RK. “Vestibular epilepsy associated with a temporoparietal lobe meningioma in a cat.” Journal of veterinary internal medicine (2025). PMID: 39890586 ↗
L4CASE_REPORTCited in: Gross and Microscopic Features, Clinical Presentation and Neurological Manifestations - [96]
d'Avella E, Somma T, Fabozzi GL et al.. “Endoscopic transorbital and transcranial multiportal resection of a sphenoorbital meningiomas with custom bone 3D printing reconstruction: Case report.” Head & neck (2024). PMID: 37994687 ↗
L4CASE_REPORTCited in: Gross and Microscopic Features - [97]
Pietrantoni A, Barresi V. “The prognostic value of H3 K27me3 in meningiomas: A review on current evidence and methodological challenges.” Histology and histopathology (2025). PMID: 39663868 ↗
L5REVIEW_NARRATIVECited in: Gross and Microscopic Features, Immunohistochemistry and Molecular Markers - [98]
Tollefsen SE, Jarmund AH, Solheim O et al.. “Human Meningiomas Reveal No Evidence of Neuroendocrine Differentiation.” APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (2026). PMID: 41769706 ↗
L5OTHERCited in: Gross and Microscopic Features, Immunohistochemistry and Molecular Markers - [99]
Iff I, Gutt-Will M, Maragkou T et al.. “The Diagnostic Value of Confocal Laser Endomicroscopy in Brain Tumours When Performed by Blinded, Untrained Neuropathologists.” Neuropathology and applied neurobiology (2026). PMID: 41545022 ↗
L5OTHERCited in: Gross and Microscopic Features, Surgical Management and Techniques - [100]
Broechner A, Maier AD, Mirian C et al.. “Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas.” Journal of neuropathology and experimental neurology (2026). PMID: 41267161 ↗
L5OTHERCited in: Gross and Microscopic Features, Immunohistochemistry and Molecular Markers - [101]
Murayi R, El-Abtah M, Ejikeme T et al.. “Validation of an immunohistochemistry-based molecular group stratification of intracranial meningiomas.” Journal of neuropathology and experimental neurology (2026). PMID: 41093285 ↗
L5OTHERCited in: Gross and Microscopic Features, Immunohistochemistry and Molecular Markers - [102]
Maeoka R, Matsuda R, Nakazawa T et al.. “Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of malignant meningioma.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025). PMID: 40300389 ↗
L5OTHERCited in: Gross and Microscopic Features - [103]
Hemmer S, Hui X, Draeger J et al.. “AlkaPhos: a novel fluorescent probe as a potential point-of-care diagnostic tool to estimate recurrence risk of meningiomas.” Neurosurgical review (2025). PMID: 39775316 ↗
L5OTHERCited in: Gross and Microscopic Features - [104]
Sharma S, Shamjetsabam ND, Chauhan K et al.. “Quantitative tissue analysis reveals AK2, COL1A1, and PLG protein signatures: targeted therapeutics for meningioma.” International journal of surgery (London, England) (2024). PMID: 39288025 ↗
L5OTHERCited in: Gross and Microscopic Features - [105]
Bargiela-Cuevas S, Marin M, Gabaldon-Ojeda M et al.. “Histone Acetyl Transferase 1 Is Overexpressed in Poor Prognosis, High-grade Meningeal and Glial Brain Cancers: Immunohistochemical and Aptahistochemical Study.” The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (2024). PMID: 39180315 ↗
L5OTHERCited in: Gross and Microscopic Features - [106]
Ieni A, Pizzimenti C, Fiorentino V et al.. “Immunohistochemical Profile of p62/SQSTM1/Sequestosome-1 in Human Low- and High-Grade Intracranial Meningiomas.” Analytical cellular pathology (Amsterdam) (2024). PMID: 39131899 ↗
L5OTHERCited in: Gross and Microscopic Features - [107]
Thirunavu V, Drumm M, McCord M et al.. “Optimizing the use of Ki-67 proliferative index as a prognostic biomarker in meningiomas using digital analysis.” Journal of neurosurgery (2024). PMID: 38968615 ↗
L5OTHERCited in: Gross and Microscopic Features - [108]
Morisako H, Sasaki T, Ikegami M et al.. “Purely endoscopic subtemporal keyhole anterior transpetrosal approach to access the petrous apex region: surgical techniques and early results.” Journal of neurosurgery (2024). PMID: 38579340 ↗
L5OTHERCited in: Gross and Microscopic Features - [109]
Tauziède-Espariat A, Masliah-Planchon J, Sievers P et al.. “A comprehensive histomolecular characterization of meningioangiomatosis: Further evidence for a precursor neoplastic lesion.” Brain pathology (Zurich, Switzerland) (2024). PMID: 38565263 ↗
L5OTHERCited in: Gross and Microscopic Features - [110]
Helal A, Hammam E, Ovenden CD et al.. “A systematic review of radiological prediction of ki 67 proliferation index of meningioma.” Neurosurgical review (2024). PMID: 39621118 ↗
L2aSR_OBSCited in: Immunohistochemistry and Molecular Markers - [111]
S S, Pendem S, K P et al.. “Machine learning based radiomics approach for outcome prediction of meningioma - a systematic review.” F1000Research (2025). PMID: 40206662 ↗
L2aSR_OBSCited in: Immunohistochemistry and Molecular Markers - [112]
Broomand Lomer N, Khalaj F, Ghorani H et al.. “MRI-derived radiomics models for prediction of Ki-67 index status in meningioma: a systematic review and meta-analysis.” Clinical imaging (2025). PMID: 39986203 ↗
L2aSR_OBSCited in: Immunohistochemistry and Molecular Markers - [113]
Brastianos PK, Dooley K, Geyer S et al.. “Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.” Nature medicine (2026). PMID: 41545592 ↗
L2bTRIAL_NONRANDOMCited in: Immunohistochemistry and Molecular Markers, Prognosis and Recurrence Patterns, Special Populations: Pediatric and Genetic Syndromes - [114]
Aktoklu M, Bıyık MO, Topsakal AS et al.. “Myeloid sarcoma of the skull base: a brief review of the literature and a rare case confused radiologically with end plaque meningioma.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 41454030 ↗
L4CASE_REPORTCited in: Immunohistochemistry and Molecular Markers, Diagnostic Imaging and Radiology, Surgical Management and Techniques - [115]
Teng H, Yu J, Pang Y et al.. “Long-term recurrence risk and temporal dynamics after resection of intracranial meningiomas: A multicenter cohort study with up to 15 years of follow-up.” Cancer (2025). PMID: 41319250 ↗
L2bCOHORTCited in: Immunohistochemistry and Molecular Markers, Surgical Management and Techniques, Radiation Therapy and Radiosurgery - [116]
Gui C, Wang JZ, Patil V et al.. “Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study.” The Lancet. Oncology (2025). PMID: 40907516 ↗
L2bCOHORTCited in: Immunohistochemistry and Molecular Markers - [117]
Shukla IY, Ebada A, Bever N et al.. “Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival.” Journal of neuro-oncology (2025). PMID: 40353934 ↗
L2bCOHORTCited in: Immunohistochemistry and Molecular Markers - [118]
Song D, Wei Q, Zhao S et al.. “Exploring a recurrence model for atypical meningioma based on multiparametric MRI radiomic and clinical characteristics: a multicenter retrospective cohort study.” Radiation oncology (London, England) (2025). PMID: 40045333 ↗
L2bCOHORTCited in: Immunohistochemistry and Molecular Markers, Clinical Presentation and Neurological Manifestations - [119]
Hugh JC, Haddon LSJ, Githaka JM. “Dexamethasone Suppresses Already Low Estrogen Receptor Levels in Meningiomas.” International journal of molecular sciences (2026). PMID: 41898640 ↗
L5REVIEW_NARRATIVECited in: Immunohistochemistry and Molecular Markers - [120]
Davoodi F, Babamohamadi Z, Khajavi M et al.. “A case of an attic lesion presenting with unilateral hearing loss, diagnosed as a meningioma: a case report and review of the literature.” Journal of medical case reports (2025). PMID: 41286999 ↗
L4CASE_REPORTCited in: Immunohistochemistry and Molecular Markers, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology - [121]
Nitturi V, Nouri SH, English C et al.. “PD-L1 positivity predicts a unique hyperaggressive tumor group within MenG C meningiomas.” JNCI cancer spectrum (2026). PMID: 41795833 ↗
L5OTHERCited in: Immunohistochemistry and Molecular Markers, Prognosis and Recurrence Patterns - [122]
Abt V, Thomas C, Wagner A et al.. “Efficacy of azacitidine in meningiomas and explorative analyses of underlying molecular mechanisms.” Neurosurgical review (2026). PMID: 41577852 ↗
L5OTHERCited in: Immunohistochemistry and Molecular Markers, Surgical Management and Techniques - [123]
Ma X, Zhao Y, Zhang K et al.. “Development of a predictive model for Ki-67 index of meningiomas by integrating deep-learning, radiomics and clinical features utilizing fully automated segmentation results.” Computer methods and programs in biomedicine (2026). PMID: 41418581 ↗
L5OTHERCited in: Immunohistochemistry and Molecular Markers, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology - [124]
Gao P, Wei J, Wang W et al.. “Brain-tumor interface-based MRI radiomics models to predict Ki-67 proliferation status of meningiomas: A multi-center study.” European journal of radiology (2026). PMID: 41325728 ↗
L5OTHERCited in: Immunohistochemistry and Molecular Markers, Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns - [125]
Umekawa M, Shinya Y, Hirano Y et al.. “Molecular insights into prognostic model for meningiomas treated with stereotactic radiosurgery: negative impacts of 1q gain on tumor control and survival.” Acta neuropathologica communications (2025). PMID: 41239509 ↗
L5OTHERCited in: Immunohistochemistry and Molecular Markers, Radiation Therapy and Radiosurgery, Special Populations: Pediatric and Genetic Syndromes - [126]
Ren L, Deng J, Xu J et al.. “SUV-max of 68Ga-DOTATATE PET/CT correlates with WHO grade and RNA risk classification in meningioma.” Journal of neuro-oncology (2025). PMID: 41129031 ↗
L5OTHERCited in: Immunohistochemistry and Molecular Markers - [127]
Bekelman NJ, Ghaith AK, Yang L et al.. “Rates of recurrence and symptom improvement following resection of spinal meningiomas in the pediatric population: individual participant data meta-analysis.” Journal of neuro-oncology (2026). PMID: 41569438 ↗
L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [128]
Pashkov A, Filimonova E, Poptsova A et al.. “Cognitive, affective and behavioral functioning in patients with olfactory groove meningiomas: a systematic review.” Neurosurgical review (2025). PMID: 40439793 ↗
L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations - [129]
Courret T, Barreau X, Engelhardt J et al.. “Endovascular stenting for intracranial venous hypertension caused by meningioma: A case series and systematic literature review.” Journal of neuroradiology = Journal de neuroradiologie (2025). PMID: 40049399 ↗
L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations - [130]
Tanti MJ, Nevitt S, Yeo M et al.. “Oedema as a prognostic factor for seizures in meningioma - a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 39969698 ↗
L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations - [131]
Khan MF, Patel S, Alnasser AA et al.. “Predicting epilepsy in patients diagnosed with intracranial meningiomas: A systematic review and meta-analysis of clinical and anatomical risk factors.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40645150 ↗
L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations - [132]
Putzler DH, Khan MF, Paulo FO et al.. “Intracranial meningioma with intratumoral hemorrhage: A systematic review of associated features and outcomes.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40090153 ↗
L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations - [133]
Guerra P, Silva I, Araújo M et al.. “Xanthomatous Meningiomas: A Systematic Review and Case Report.” Turkish neurosurgery (2025). PMID: 41165380 ↗
L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology - [134]
Ogura T, Fukuhara N, Yamaguchi-Okada M et al.. “Clinical features of intrasellar meningiomas treated with endoscopic endonasal surgery: a case series and comparison with other parasellar meningiomas and a literature review.” Neurosurgical review (2025). PMID: 40189713 ↗
L4CASE_REPORTCited in: Clinical Presentation and Neurological Manifestations - [135]
Qin J, Li C, Fu J et al.. “Construction and application of a nomogram model for predicting postoperative cerebral edema in meningiomas based on radiomics and clinical features.” Acta radiologica (Stockholm, Sweden : 1987) (2025). PMID: 40474660 ↗
L1bRCTCited in: Clinical Presentation and Neurological Manifestations - [136]
Cook WH, Gillespie CS, Bakhsh A et al.. “Epileptogenesis in meningioma: Theories, putative biomarkers, and postoperative risk.” Epilepsia (2025). PMID: 40729436 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation and Neurological Manifestations - [137]
Abdullaev AN, Dzhindzhikhadze RS, Polyakov AV et al.. “[Approaches in microsurgery for olfactory meningiomas: a systematic review and meta-analysis].” Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko (2026). PMID: 41930435 ↗
L2aSR_OBSCited in: Clinical Presentation and Neurological Manifestations, Surgical Management and Techniques - [138]
Lin LC, Chow WH, Wu YJ et al.. “Salvage boron neutron capture therapy for recurrent intracranial malignant meningioma: Case report and literature review.” Medicine (2025). PMID: 40760503 ↗
L4CASE_REPORTCited in: Clinical Presentation and Neurological Manifestations - [139]
Chang HF, Maimaitiaili N, Huo JF et al.. “Clinical and pathological characteristics of pulmonary meningioma: a case report and literature review.” The Journal of international medical research (2025). PMID: 39981620 ↗
L4CASE_REPORTCited in: Clinical Presentation and Neurological Manifestations - [140]
Tolppola L, Pohjola A, Vasankari V et al.. “3D digital exoscope is safe tool in the surgery of olfactory groove meningiomas.” Acta neurochirurgica (2026). PMID: 41792536 ↗
L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [141]
Basaran AE, Braune M, Barrantes-Freer A et al.. “FOXC1 expression and radiological predictors of peritumoral brain edema in meningiomas.” Journal of neuro-oncology (2026). PMID: 41632362 ↗
L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns - [142]
Wang Z, Chen L, Li Y et al.. “Integrating diffusion-weighted MRI radiomics features to predict brain invasion of meningiomas.” Neurosurgical review (2025). PMID: 41354891 ↗
L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns - [143]
Bin-Alamer O, Taori S, Abou-Al-Shaar H et al.. “Early outcomes of Gamma Knife stereotactic radiosurgery for symptomatic intracranial meningiomas in octogenarians: technique analysis and rationale.” Journal of neuro-oncology (2025). PMID: 41186800 ↗
L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Radiation Therapy and Radiosurgery - [144]
Dallan I, Serioli S, de Notaris M et al.. “Transorbital management of selected spheno-orbital meningiomas: Insights from a multicentric retrospective Italian study of 52 cases.” Neurosurgical review (2025). PMID: 41081961 ↗
L5OTHERCited in: Clinical Presentation and Neurological Manifestations - [145]
Sotera G, Forte C, D'Urso DG et al.. “In Silico Identification of circPIM1/miR-16-5p/miR-195-5p/PIM1 Feed-Forward Loop in Recurrent Grade 2 Meningioma.” International journal of molecular sciences (2025). PMID: 40943185 ↗
L5OTHERCited in: Clinical Presentation and Neurological Manifestations, Special Populations: Pediatric and Genetic Syndromes - [146]
Jacquesson T, Goichot L, Beaumont A et al.. “High-resolution T2-weighted MRI versus tractography to predict cranial nerve anatomy in skull base tumors: a retrospective 132-case series.” Journal of neurosurgery (2026). PMID: 41576385 ↗
L4CASE_REPORTCited in: Diagnostic Imaging and Radiology - [147]
Kondo A, Umezawa H, Taga M et al.. “Salvage Reconstruction With Recycled Flap Pedicles in Head-and-Neck Surgery: A Report of Two Cases.” Microsurgery (2025). PMID: 41190748 ↗
L4CASE_REPORTCited in: Diagnostic Imaging and Radiology, Surgical Management and Techniques - [148]
Khiralla A, Giotta Lucifero A, Al-Mefty O. “Median medullary perforators: Anatomical, surgical, and clinical significance in foramen magnum meningiomas.” Neurosurgical review (2025). PMID: 41099782 ↗
L4CASE_REPORTCited in: Diagnostic Imaging and Radiology - [149]
Tatoğlu MT, Atalay B. “Incidental detection of anterior clinoid meningioma on [⁶⁸Ga]Ga-DOTATATE PET/CT in a patient with suspected neuroendocrine tumor.” Neuroradiology (2025). PMID: 41026227 ↗
L4CASE_REPORTCited in: Diagnostic Imaging and Radiology - [150]
Coffee E, Elshiekh C, Budhu JA. “Imaging in Neuro-oncology.” Seminars in neurology (2025). PMID: 41082927 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Imaging and Radiology - [151]
Gao M, Zang H, Zhao W et al.. “Unraveling glymphatic disruption in brain tumors: Insights from perivascular space network analysis.” International journal of cancer (2026). PMID: 41795205 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology - [152]
Sadeghzadeh N, Correia JA, Shen J et al.. “A single MRI scan contains sufficient imaging information for accurate prediction of meningioma growth risk.” NeuroImage. Clinical (2026). PMID: 41780349 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology - [153]
Pineda-Ibarra C, Puig J, Nuñez-Leiva D et al.. “Brain MRI Radiomic First-Order Features for Presurgical Prediction of Meningioma Grading.” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2026). PMID: 41635960 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [154]
Duarte Gomes M, Campos Cardoso HM, Coutinho R et al.. “Diagnostic Value of Routine MRI Parameters in Identifying High-Grade Intracranial Meningiomas.” Neuroradiology (2026). PMID: 41518389 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns - [155]
Kikuchi K, Togao O, Yamashita K et al.. “Relaxometry assessment of meningioma consistency using quantitative magnetic resonance imaging.” Neuroradiology (2026). PMID: 41457092 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology - [156]
Tan G, Feng Z, Xiao G et al.. “Machine learning based radiomics outperforms tumor/cerebellar peduncle T2-weighted imaging intensity ratios and ROIs-based apparent diffusion coefficient measurements in the preoperative prediction of meningioma consistency.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41406538 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology, Prognosis and Recurrence Patterns - [157]
Comeau MO, Gascon F, Corbeil M et al.. “Influence of dural attachment on remnant progression after subtotal resection in WHO grade 1 meningioma.” Acta neurochirurgica (2025). PMID: 41381949 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology, Surgical Management and Techniques, Prognosis and Recurrence Patterns - [158]
Garcia-Garcia S, Laajava J, Takala J et al.. “MRI radiomic signature predicts peritumoral brain edema resolution following meningioma surgery.” Acta neurochirurgica (2025). PMID: 41339597 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology - [159]
Turcas A, Bodensohn R, Clerici E et al.. “Patterns of care in primary brain tumour Reirradiation: A survey by the ESTRO CNS focus Group.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41290090 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology, Radiation Therapy and Radiosurgery, Guidelines and Resources - [160]
Bazani A, Bagnalasta M, Fontana G et al.. “Investigation of the combined role of dose and dose-averaged LET in the occurrence of brain necrosis after intensity modulated proton therapy for meningioma and solitary fibrous tumours.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41271170 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology, Radiation Therapy and Radiosurgery - [161]
Kaijser M, Feychting M, Skare S et al.. “The validity of the information on date of diagnosis of intracranial tumors in the Swedish cancer register.” European journal of epidemiology (2026). PMID: 41137898 ↗
L5OTHERCited in: Diagnostic Imaging and Radiology - [162]
El-Abtah ME, Murayi R, Lee J et al.. “Radiological Differentiation Between Intracranial Meningioma and Solitary Fibrous Tumor/Hemangiopericytoma: A Systematic Literature Review.” World neurosurgery (2023). PMID: 36403933 ↗
L2aSR_OBSCited in: Differential Diagnosis, Guidelines and Resources - [163]
Hicks WH, Pernik MN, Adeyemo E et al.. “Contiguous Meningioma and B-Cell Lymphoma: A Scoping Review and Case Illustration.” World neurosurgery (2022). PMID: 34798339 ↗
L2aSR_OBSCited in: Differential Diagnosis - [164]
Ashizawa K, Ogura K, Nagase S et al.. “A collision tumor of solitary fibrous tumor/hemangiopericytoma and meningioma: A case report with literature review.” Pathology international (2021). PMID: 34411369 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [165]
Beutler BD, Lee J, Edminster S et al.. “Intracranial meningioma: A review of recent and emerging data on the utility of preoperative imaging for management.” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2024). PMID: 39113129 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [166]
Barden MM, Omuro AM. “Top advances of the year: Neuro-oncology.” Cancer (2023). PMID: 36825454 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [167]
Yamashita D, Suehiro S, Kohno S et al.. “Intracranial anaplastic solitary fibrous tumor/hemangiopericytoma: immunohistochemical markers for definitive diagnosis.” Neurosurgical review (2021). PMID: 32671693 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [168]
Helgager J, Driver J, Hoffman S et al.. “Molecular Advances in Central Nervous System Mesenchymal Tumors.” Surgical pathology clinics (2020). PMID: 32389268 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [169]
Glinka P, Sobstyl M, Rymkiewicz G et al.. “Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the dura mimicking meningioma: a case report and literature review.” Folia neuropathologica (2024). PMID: 38741437 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [170]
La Rocca G, Auricchio AM, Mazzucchi E et al.. “Intracranial dural based marginal zone MALT-type B-cell lymphoma: a case - Based update and literature review.” British journal of neurosurgery (2023). PMID: 34180316 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [171]
Engelhardt J, de Luzinais MG, Ollivier M et al.. “A case series of percutaneous transforamen ovale biopsies in cavernous sinus lesions.” Acta neurochirurgica (2022). PMID: 34136959 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [172]
Yang Z, Su X, Yuan Z et al.. “Mixed reality holographic navigation for intracranial lesions using HoloLens 2: A pilot study and literature review.” Clinical neurology and neurosurgery (2025). PMID: 40570755 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [173]
Horowitz T, Tabouret E, Graillon T et al.. “Contribution of nuclear medicine to the diagnosis and management of primary brain tumours.” Revue neurologique (2023). PMID: 36934021 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [174]
Park BJ, Dougherty MC, Noeller J et al.. “Spinal Meningioma in Adults: Imaging Characteristics, Surgical Outcomes, and Risk Factors for Recurrence.” World neurosurgery (2022). PMID: 35605940 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [175]
McNab AA, Jones RS, Hardy TG. “Spheno-orbital Lesions-A Major Review of Nonmeningioma Causes.” Ophthalmic plastic and reconstructive surgery (Unknown). PMID: 33782321 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [176]
Munawar K, Nayak G, Fatterpekar GM et al.. “Cavernous sinus lesions.” Clinical imaging (2020). PMID: 32574933 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [177]
Garg S, Gude G, Chatterjee D et al.. “Primary Dural Acute Lymphoblastic Leukaemia/Lymphoma Masquerading Meningioma: Report of a Case and Review of Literature.” Neurology India (2023). PMID: 37929440 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [178]
Ren L, Deng J, Feng A et al.. “Long-term follow-up outcomes in intracranial solitary fibrous tumor compared with meningioma: a propensity score matching study.” Journal of neurosurgery (2025). PMID: 40882230 ↗
L5OTHERCited in: Differential Diagnosis - [179]
Kaley TJ, Grommes C, Coffee E et al.. “Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma.” Neuro-oncology (2025). PMID: 40842355 ↗
L5OTHERCited in: Differential Diagnosis - [180]
Toth LF, Majós C, Pons-Escoda A et al.. “Machine Learning Analysis of Single-Voxel Proton MR Spectroscopy for Differentiating Solitary Fibrous Tumors and Meningiomas.” NMR in biomedicine (2025). PMID: 40186532 ↗
L5OTHERCited in: Differential Diagnosis - [181]
Fiorante A, Woolman M, Munoz DG et al.. “A molecular array for 10-second diagnosis of common spinal tumor types with picosecond infrared laser mass spectrometry.” Neuro-oncology (2025). PMID: 39980445 ↗
L5OTHERCited in: Differential Diagnosis - [182]
Mirchia K, Choudhury A, Joseph T et al.. “Meningeal solitary fibrous tumor cell states phenocopy cerebral vascular development and homeostasis.” Neuro-oncology (2025). PMID: 39207122 ↗
L5OTHERCited in: Differential Diagnosis - [183]
Zhang L, Li C, Marhaba Aziz et al.. “ITF2357 induces cell cycle arrest and apoptosis of meningioma cells via the PI3K-Akt pathway.” Medical oncology (Northwood, London, England) (2022). PMID: 36445551 ↗
L5OTHERCited in: Differential Diagnosis - [184]
Aunan-Diop JS, Andersen MCS, Friismose AI et al.. “Virtual magnetic resonance elastography predicts the intraoperative consistency of meningiomas.” Journal of neuroradiology = Journal de neuroradiologie (2023). PMID: 36343849 ↗
L5OTHERCited in: Differential Diagnosis - [185]
Liu X, Deng J, Sun Q et al.. “Differentiation of intracranial solitary fibrous tumor/hemangiopericytoma from atypical meningioma using apparent diffusion coefficient histogram analysis.” Neurosurgical review (2022). PMID: 35303202 ↗
L5OTHERCited in: Differential Diagnosis - [186]
Marletta S, Luchini C, Sperandio N et al.. “CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.” Virchows Archiv : an international journal of pathology (2022). PMID: 35212813 ↗
L5OTHERCited in: Differential Diagnosis - [187]
Sloan EA, Gupta R, Koelsche C et al.. “Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas.” Brain pathology (Zurich, Switzerland) (2022). PMID: 34821426 ↗
L5OTHERCited in: Differential Diagnosis - [188]
Apra C, Guillemot D, Frouin E et al.. “Molecular description of meningeal solitary fibrous tumors/hemangiopericytomas compared to meningiomas: two completely separate entities.” Journal of neuro-oncology (2021). PMID: 34417711 ↗
L5OTHERCited in: Differential Diagnosis - [189]
Nagai Yamaki V, de Souza Godoy LF, Alencar Bandeira G et al.. “Dural-based lesions: is it a meningioma?” Neuroradiology (2021). PMID: 33459822 ↗
L5OTHERCited in: Differential Diagnosis - [190]
Yoo J, Park HH, Yun IS et al.. “Clinical applications of the endoscopic transorbital approach for various lesions.” Acta neurochirurgica (2021). PMID: 33394139 ↗
L5OTHERCited in: Differential Diagnosis - [191]
Hong J, Moes G, Lai J. “Intraoperative Frozen Section Diagnosis of Brain Rosai-Dorfman Disease Clinically and Radiologically Mimicking Meningioma.” In vivo (Athens, Greece) (2025). PMID: 41167660 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [192]
Arnautovic KI, Lasica N. “Update on anterior clinoid process removal in anterior clinoid meningioma surgery: literature review, and a new didactical concept.” Acta neurochirurgica (2025). PMID: 41432809 ↗
L2aSR_OBSCited in: Surgical Management and Techniques - [193]
Feng QJ, Zheng Y, Cheong TKF et al.. “Revisiting traditional transcranial approaches for anterior skull base meningiomas: a systematic review and meta-analysis of transcranial approaches against minimally invasive surgical techniques.” Neurosurgical review (2025). PMID: 41388197 ↗
L2aSR_OBSCited in: Surgical Management and Techniques, Prognosis and Recurrence Patterns - [194]
Sivanathan S, Al-Rabadi J, Alexander KG et al.. “Endoscopic Endonasal Approach for Primary Optic Nerve Sheath Meningioma: A Systematic Review.” World neurosurgery (2026). PMID: 41570978 ↗
L2aSR_OBSCited in: Surgical Management and Techniques, Prognosis and Recurrence Patterns - [195]
Hajikarimloo B, Tos SM, Mohammadzadeh I et al.. “Efficacy and Safety of Stereotactic Radiosurgery for Cerebellopontine Angle Meningiomas: A Systematic Review and Meta-Analysis.” Neuro-Chirurgie (2026). PMID: 41397526 ↗
L2aSR_OBSCited in: Surgical Management and Techniques, Radiation Therapy and Radiosurgery, Prognosis and Recurrence Patterns - [196]
Quintin K, Josset S, Latorzeff I et al.. “Radiotherapy of benign intracranial tumours: 2025 update.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025). PMID: 41273886 ↗
L1cGUIDELINECited in: Surgical Management and Techniques, Radiation Therapy and Radiosurgery, Guidelines and Resources - [197]
Abdelgadir J, Nadel J, Zachem TJ et al.. “Deciding when and when not to reconstruct the orbit: How I do it.” Acta neurochirurgica (2026). PMID: 41691074 ↗
L4CASE_REPORTCited in: Surgical Management and Techniques - [198]
Al-Hamid S, Grellmann F, Reiser J et al.. “Combining 3D printing and elastographic characterization: A novel sphenoid wing meningioma simulation model for neurosurgical training.” Neurosurgical review (2026). PMID: 41535607 ↗
L5OTHERCited in: Surgical Management and Techniques - [199]
Sakaeyama Y, Kubota S, Abe M et al.. “Usefulness of a 3 Dimensional-printed Head Model with Two-layered Dura and Cerebellar Tentorium for Transpetrosal Approach Training.” Neurologia medico-chirurgica (2026). PMID: 41526252 ↗
L5OTHERCited in: Surgical Management and Techniques - [200]
Yamashiro K, Kozaki T, Fukumoto H et al.. “Risk assessment of brain retraction injury based on quantitative evaluation of brain retraction distance during skull-base meningioma surgery.” Neurosurgical review (2026). PMID: 41489755 ↗
L5OTHERCited in: Surgical Management and Techniques - [201]
Fariselli L, Marzoli SB, Morlino S et al.. “Hypofractionated Radiosurgery (25 Gy/5 Fractions) for Optic Nerve Sheath Meningiomas: Results From an Exploratory Phase 2 Prospective Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 40349855 ↗
L2bTRIAL_NONRANDOMCited in: Radiation Therapy and Radiosurgery - [202]
Perlow HK, Raleigh DR, Wang TJC et al.. “Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas.” International journal of radiation oncology, biology, physics (2025). PMID: 39701546 ↗
L1cGUIDELINECited in: Radiation Therapy and Radiosurgery, Guidelines and Resources - [203]
Gomes FC, Larcipretti ALL, Mariano ÍGGF et al.. “GammaKnife radiosurgery for meningiomas in neurofibromatosis type II patients: a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 40237947 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery, Special Populations: Pediatric and Genetic Syndromes - [204]
Cook WH, Khalil F, Gillespie CS et al.. “Health-related quality-of-life outcomes in CNS WHO grade 2 and 3 meningioma: a systematic review.” Neurosurgical review (2025). PMID: 40011234 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery - [205]
Habibi MA, Mirjani MS, Ahmadvand MH et al.. “Gamma knife stereotactic radiosurgery for neurofibromatosis 2 (NF2)-associated meningiomas; a systematic review and meta-analysis.” Acta neurochirurgica (2025). PMID: 39907804 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery, Special Populations: Pediatric and Genetic Syndromes - [206]
Javadnia P, Bahadori AR, Ghanaatpisheh A et al.. “The safety and efficacy of robotic radiosurgery and radiotherapy in the management of skull base tumors: a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 39792270 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery - [207]
Lesueur P, Clarisse B, Lequesne J et al.. “Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).” BMC cancer (2024). PMID: 39736544 ↗
L2bTRIAL_NONRANDOMCited in: Radiation Therapy and Radiosurgery - [208]
Hajikarimloo B, Tos SM, Habibi MA et al.. “Efficacy and safety of stereotactic radiosurgery for foramen magnum meningiomas: a systematic review and meta-analysis.” Journal of neurosurgical sciences (2025). PMID: 40662245 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery - [209]
Hajikarimloo B, Tos SM, Mohammadzadeh I et al.. “Stereotactic radiosurgery for optic nerve sheath meningiomas: A comprehensive systematic review and meta-analysis.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40580760 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery - [210]
Hajikarimloo B, Tos SM, Mohammadzadeh I et al.. “Efficacy and safety of stereotactic radiosurgery for large meningiomas: A comprehensive systematic review and meta-analysis.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40505253 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery - [211]
Hajikarimloo B, Mohammadzadeh I, Tos SM et al.. “Stereotactic radiosurgery for tumor-related trigeminal neuralgia: a systematic review and meta-analysis.” BMC neurology (2025). PMID: 40319265 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery - [212]
Chow A, Hovis GEA, Ghodrati F et al.. “Early-onset stroke-like migraine attacks after radiation therapy syndrome: A case report and review of the literature.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 39675213 ↗
L2aSR_OBSCited in: Radiation Therapy and Radiosurgery - [213]
Kumar R, Carlstrom LP, Morshed R et al.. “Single-Fraction Stereotactic Radiosurgery as Primary Management of Sporadic Meningiomas: A 25-Year Cohort Study.” Neurosurgery (2025). PMID: 40476726 ↗
L2bCOHORTCited in: Radiation Therapy and Radiosurgery - [214]
Nguyen BT, Huynh CT, Nguyen TM et al.. “Gamma knife radiosurgery for benign tumor-related trigeminal neuralgia: a single-institution retrospective study.” Neurosurgical review (2025). PMID: 39960553 ↗
L2bCOHORTCited in: Radiation Therapy and Radiosurgery - [215]
Lesueur P, Joly F, Clarisse B et al.. “Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG).” Radiation oncology (London, England) (2025). PMID: 39881369 ↗
L2bCOHORTCited in: Radiation Therapy and Radiosurgery - [216]
Hotsinpiller WS, Thomas EM, Tsekouras I et al.. “Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity.” Journal of neuro-oncology (2025). PMID: 41118008 ↗
L5OTHERCited in: Radiation Therapy and Radiosurgery - [217]
Alhosanie TN, Hammo B, Klaib AF et al.. “Integrating artificial intelligence with Gamma Knife radiosurgery in treating meningiomas and schwannomas: a review.” Neurosurgical review (2025). PMID: 40965768 ↗
L5REVIEW_NARRATIVECited in: Radiation Therapy and Radiosurgery - [218]
Wang Y, Wang C, Yin S et al.. “Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.” CNS neuroscience & therapeutics (2025). PMID: 41358608 ↗
L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments, Prognosis and Recurrence Patterns - [219]
Nakhate V, Ly I, Muzikansky A et al.. “Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.” Journal of neuro-oncology (2025). PMID: 40434540 ↗
L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments, Special Populations: Pediatric and Genetic Syndromes - [220]
Abikenari M, Regev A, Himic V et al.. “The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.” Journal of neuro-oncology (2025). PMID: 40392516 ↗
L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments - [221]
Kotecha R, Akdemir EY, Kutuk T et al.. “Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.” Neuro-oncology (2025). PMID: 39807850 ↗
L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments - [222]
Dijkstra BM, Cordia QCF, Nonnekens J et al.. “Bevacizumab-IRDye800CW for tumor detection in fluorescence-guided meningioma surgery (LUMINA trial): a single-center phase I study.” Journal of neurosurgery (2024). PMID: 38968617 ↗
L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments - [223]
Deng MY, Maas SLN, Hinz F et al.. “Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial.” Neuro-oncology (2024). PMID: 38079455 ↗
L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments - [224]
Bosio A, Cerretti G, Padovan M et al.. “Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).” Trials (2025). PMID: 40759981 ↗
L1bRCTCited in: Systemic Therapy and Emerging Treatments - [225]
Jensen LR, Maier AD, Juratli TA et al.. “The concept, intention, and evaluation of the term treatment-refractory meningioma.” Journal of neuro-oncology (2025). PMID: 40760312 ↗
L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments - [226]
Hajikarimloo B, Hasanzade A, Sabbagh Alvani M et al.. “Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis.” Neurosurgical review (2024). PMID: 39327340 ↗
L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments - [227]
Watanabe G, Young K, Rauber E et al.. “A systematic review of extraneural meningioma metastasis: timing, evolution and outlook.” Journal of neuro-oncology (2024). PMID: 38530549 ↗
L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments - [228]
Casey DL, Vogelius IR, Brodin NP et al.. “Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review.” International journal of radiation oncology, biology, physics (2024). PMID: 37777927 ↗
L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments - [229]
Himič V, Burman RJ, Fountain DM et al.. “Metastatic meningioma: a case series and systematic review.” Acta neurochirurgica (2023). PMID: 37491650 ↗
L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments, Guidelines and Resources - [230]
Kaye J, Na J, Atluri S et al.. “Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review.” World neurosurgery (2024). PMID: 38901486 ↗
L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments - [231]
Boursier C, Zaragori T, Imbert L et al.. “177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review.” The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... (2024). PMID: 39026463 ↗
L2aSR_OBSCited in: Systemic Therapy and Emerging Treatments - [232]
Galluzzo D, Chen C, Alok K et al.. “Evolving Treatment Paradigms of Meningiomas; a Precision Medicine Perspective.” Current neurology and neuroscience reports (2025). PMID: 41085787 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments - [233]
Yamazawa E, Sullivan E, Wakimoto H et al.. “Emerging targeted therapies in meningiomas.” Current opinion in neurology (2025). PMID: 41069194 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments - [234]
Quach S, Simon M. “Diagnostic advances and challenges in meningioma.” Expert review of neurotherapeutics (2025). PMID: 40826833 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments - [235]
Albert NL, Tabouret E, Le Rhun E et al.. “[177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial.” Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2026). PMID: 40774695 ↗
L2bTRIAL_NONRANDOMCited in: Systemic Therapy and Emerging Treatments - [236]
Kooi EJ, Marcelis L, Wesseling P. “Pathological diagnosis of central nervous system tumours in adults: what's new?” Pathology (2025). PMID: 39818455 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments - [237]
Pereira BJA, de Almeida AN, Paiva WS et al.. “Impact on natural history of atypical meningioma after changes in 2016 edition of the world health organization (WHO) classification of central nervous system tumors: a literature review.” Neurosurgical review (2024). PMID: 39340638 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments - [238]
Pourhadi N, Meaidi A, Friis S et al.. “Menopausal hormone therapy and central nervous system tumors: Danish nested case-control study.” PLoS medicine (2023). PMID: 38113227 ↗
L3bCASE_CONTROLCited in: Systemic Therapy and Emerging Treatments - [239]
Li Y, Drappatz J. “Advances in the systemic therapy for recurrent meningiomas and the challenges ahead.” Expert review of neurotherapeutics (2023). PMID: 37695700 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments - [240]
Tamura R. “Drug Repositioning for Refractory Benign Tumors of the Central Nervous System.” International journal of molecular sciences (2023). PMID: 37629179 ↗
L5REVIEW_NARRATIVECited in: Systemic Therapy and Emerging Treatments - [241]
Nguyen DC, Nader C, Bélanger K et al.. “A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.” Current oncology (Toronto, Ont.) (2025). PMID: 41002586 ↗
L2bCOHORTCited in: Systemic Therapy and Emerging Treatments - [242]
Fukumura M, Kashiwagi H, Yoshimura K et al.. “Perfusion changes associated with intratumoral embolization and feeder occlusion for meningiomas: an arterial spin labeling study.” Acta neurochirurgica (2026). PMID: 41673213 ↗
L5OTHERCited in: Prognosis and Recurrence Patterns - [243]
Duckett D, Santana-Santos L, McCord M et al.. “Development, validation, and utility of a clinically applicable methylation classifier for recurrence risk prediction in meningiomas.” Acta neuropathologica communications (2025). PMID: 41466325 ↗
L5OTHERCited in: Prognosis and Recurrence Patterns - [244]
Zhu Y, Rudolf MA, Conway K et al.. “A practical approach for assessing high-grade diffuse gliomas and meningiomas.” Human pathology (2026). PMID: 41419116 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Recurrence Patterns - [245]
Wach J, Vychopen M, Basaran AE et al.. “Overall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis.” Journal of neuro-oncology (2025). PMID: 39779595 ↗
L2aSR_OBSCited in: Special Populations: Pediatric and Genetic Syndromes - [246]
Zuniga RDDR, Carrijo GS, do Vale MR et al.. “Pathogenic Variants and Prognosis in Meningiomas: A Systematic Review and Meta-Analysis.” World neurosurgery (2025). PMID: 40254182 ↗
L2aSR_OBSCited in: Special Populations: Pediatric and Genetic Syndromes - [247]
Nobee A, Xu M, Seth A et al.. “Atypical Intraparenchymal Meningioma with YAP1-MAML2 Fusion in a Young Adult Male: A Case Report and Mini Literature Review.” International journal of molecular sciences (2023). PMID: 37628996 ↗
L4CASE_REPORTCited in: Special Populations: Pediatric and Genetic Syndromes - [248]
Sahm F, Aldape KD, Brastianos PK et al.. “cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.” Neuro-oncology (2025). PMID: 39212325 ↗
L5REVIEW_NARRATIVECited in: Special Populations: Pediatric and Genetic Syndromes - [249]
Grilli F, Smaili HY, Bianchi F et al.. “Hyperostotic meningiomas in children. A case-based update.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2024). PMID: 39661177 ↗
L4CASE_REPORTCited in: Special Populations: Pediatric and Genetic Syndromes - [250]
Kalamarides M, Pathmanaban O, Peyre M et al.. “Surgery in NF2-Schwannomatosis.” Familial cancer (2025). PMID: 41420725 ↗
L5REVIEW_NARRATIVECited in: Special Populations: Pediatric and Genetic Syndromes - [251]
Gregory GE, Haley MJ, Jones AP et al.. “The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis.” Acta neuropathologica communications (2025). PMID: 41437121 ↗
L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes - [252]
Chang LS, Oblinger JL, Wu LMN et al.. “Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN-Associated and Sporadic NF2-Deficient Meningiomas.” Cancer research communications (2026). PMID: 41417846 ↗
L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes - [253]
Deboeuf L, Keraudy A, Picart T et al.. “Prevalence, natural history and surgical outcome of spinal meningiomas in NF2-related schwannomatosis.” Journal of neuro-oncology (2025). PMID: 40958044 ↗
L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes - [254]
Hirano Y, Miyawaki S, Sakai Y et al.. “Integrated molecular and detailed anatomical profiling identifies a prognostically adverse subtype of posterior fossa meningiomas: high-risk copy number alterations are associated with midline predilection and predict poor prognosis.” Acta neuropathologica communications (2025). PMID: 40775657 ↗
L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes - [255]
Koçyiğit S, Chavez MM, Orhun Ö et al.. “Posterior parasagittal meningiomas display aggressive features independent of size: a multicenter analysis.” Journal of neuro-oncology (2025). PMID: 40569492 ↗
L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes - [256]
Fan H, Li X, Zhao Y et al.. “Decoding meningioma prognosis with multi-omics: macrophage diversity, immune-CNV interplay, and novel SPP1-targeted strategies.” Journal of neuro-oncology (2025). PMID: 40522564 ↗
L5OTHERCited in: Special Populations: Pediatric and Genetic Syndromes - [257]
Albert NL, Preusser M, Traub-Weidinger T et al.. “Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.” European journal of nuclear medicine and molecular imaging (2024). PMID: 38898354 ↗
L1cGUIDELINECited in: Guidelines and Resources - [258]
Martz N, Salleron J, Dhermain F et al.. “Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline.” Radiation oncology (London, England) (2023). PMID: 37408055 ↗
L1cGUIDELINECited in: Guidelines and Resources - [259]
Goldbrunner R, Stavrinou P, Jenkinson MD et al.. “EANO guideline on the diagnosis and management of meningiomas.” Neuro-oncology (2021). PMID: 34181733 ↗
L1cGUIDELINECited in: Guidelines and Resources - [260]
Marchetti M, Sahgal A, De Salles AAF et al.. “Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline.” Neurosurgery (2020). PMID: 32463867 ↗
L1cGUIDELINECited in: Guidelines and Resources - [261]
Dissaux G, Josset S, Thillays F et al.. “Radiotherapy of benign intracranial tumours.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2022). PMID: 34953692 ↗
L1cGUIDELINECited in: Guidelines and Resources - [262]
Aziz HF, Bakhshi SK, Tariq R et al.. “Consensus guidelines for the management of primary supra-tentorial intraventricular tumour for low- and middle-income countries.” JPMA. The Journal of the Pakistan Medical Association (2024). PMID: 39262081 ↗
L1cGUIDELINECited in: Guidelines and Resources - [263]
Enam SA, Masroor M, Bakhshi SK et al.. “Consensus guidelines for the management of intracranial meningioma for low- and middle-income countries.” JPMA. The Journal of the Pakistan Medical Association (2024). PMID: 39262076 ↗
L1cGUIDELINECited in: Guidelines and Resources - [264]
Khaboushan AS, Ohadi MAD, Amani H et al.. “Stereotactic radiosurgery for intraventricular meningioma: a systematic review and meta-analysis.” Acta neurochirurgica (2024). PMID: 38980438 ↗
L2aSR_OBSCited in: Guidelines and Resources - [265]
Fouda MA, Kallman S, Boorstin R et al.. “The unseen impact - a deep dive into neurocognitive impairment among patients with intracranial meningiomas: a comprehensive systematic review of the literature.” Neurosurgical review (2024). PMID: 38922363 ↗
L2aSR_OBSCited in: Guidelines and Resources - [266]
Hallak H, Rindler R, Dang D et al.. “Trigeminal neuralgia pain outcomes following microsurgical resection versus stereotactic radiosurgery for petroclival meningiomas: a systematic review and meta-analysis.” Journal of neurosurgery (2024). PMID: 37542438 ↗
L2aSR_OBSCited in: Guidelines and Resources - [267]
Watanabe S, Nonaka T, Maeda M et al.. “Efficacy Endpoints in Phase II Clinical Trials for Meningioma: An Analysis of Recent Clinical Trials.” Therapeutic innovation & regulatory science (2023). PMID: 36602756 ↗
L2bTRIAL_NONRANDOMCited in: Guidelines and Resources - [268]
Chen L, Li DH, Lu YH et al.. “Preoperative Embolization Versus Direct Surgery of Meningiomas: A Meta-Analysis.” World neurosurgery (2019). PMID: 30954743 ↗
L2aSR_OBSCited in: Guidelines and Resources - [269]
Vassantachart AK, Ehret F, Chen E et al.. “A Case-based Guide for World Health Organization (WHO) Grade 2 Meningioma Radiosurgery and Radiation Therapy from The Radiosurgery Society.” Practical radiation oncology (2024). PMID: 38970567 ↗
L4CASE_REPORTCited in: Guidelines and Resources - [270]
Wang C, Chen Y, Zhang L et al.. “Thoracic psammomatous meningioma with osseous metaplasia: a controversial diagnosis of a case report and literature review.” World journal of surgical oncology (2019). PMID: 31445511 ↗
L4CASE_REPORTCited in: Guidelines and Resources - [271]
Fuchs F, Marschner SN, Hofmaier J et al.. “SSTR PET/CT for skull base low-grade meningioma: a critical tool for accurate gross tumor volume delineation in radiotherapy?” Radiation oncology (London, England) (2025). PMID: 40983935 ↗
L5OTHERCited in: Guidelines and Resources - [272]
Landry AP, Wang JZ, Yefet LS et al.. “Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies.” Neuro-oncology (2025). PMID: 39851181 ↗
L5OTHERCited in: Guidelines and Resources - [273]
Sadashiva N, Goyal-Honavar A, Nadeem M et al.. “Surgical outcomes of trigonal intraventricular meningiomas: a single-centre study.” Neurosurgical review (2024). PMID: 38965148 ↗
L5OTHERCited in: Guidelines and Resources - [274]
Wang JZ, Landry AP, Raleigh DR et al.. “Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.” Neuro-oncology (2024). PMID: 38695575 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [275]
Gu H, Yang C, Al-Kharouf I et al.. “Enhancing mitosis quantification and detection in meningiomas with computational digital pathology.” Acta neuropathologica communications (2024). PMID: 38212848 ↗
L5OTHERCited in: Guidelines and Resources - [276]
Chen C, Teng Y, Tan S et al.. “Performance Test of a Well-Trained Model for Meningioma Segmentation in Health Care Centers: Secondary Analysis Based on Four Retrospective Multicenter Data Sets.” Journal of medical Internet research (2023). PMID: 38100181 ↗
L5OTHERCited in: Guidelines and Resources - [277]
Bove I, Cheok S, Ruzevick JJ et al.. “Endoscopic Endonasal and Keyhole Surgery for Skull Base Meningiomas.” Neurosurgery clinics of North America (2023). PMID: 37210128 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [278]
Clynch AL, Norrington M, Mustafa MA et al.. “Cranial meningioma with bone involvement: surgical strategies and clinical considerations.” Acta neurochirurgica (2023). PMID: 36877330 ↗
L5OTHERCited in: Guidelines and Resources